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Executive Summary  
The Transatlantic Task Force on Antimicrobial Resistance (TATFAR) fosters cooperation between the 
European Union (EU)  and the United States (US) on the issue of antimicrobial resistance. The first 
TATFAR recommendation refers to appropriate use of antimicrobials in human medicine through 
hospital Antimicrobial Stewardship Programs (ASPs) and, specifically, to the development of common 
structure and process indicators of ASP. These indicators should allow characterization of programs and 
comparisons among healthcare systems in EU and US. 
To this end, a multidisciplinary expert group, coordinated by the European Centre for Disease 
Prevention and Control (ECDC) and US Centers for Disease Control and Prevention (CDC), was formed. 
The group consisted of 20 experts including representation of nine EU member states and six US states. 
The expert group participated in a structured consensus process (modified Delphi method) to facilitate 
the international collaboration and ensure the equal involvement of all experts. The process was 
conducted between March and May 2014 and was concluded by a group consensus meeting in June 
2014. An initial list of indicators was developed based on previous indicators, available guidance and a 
review of the literature, including published systematic reviews. The domains assessed were: 
Governance and Management; Human Resources; Laboratory; Information Technology; Education; 
Policies for Appropriate Use; Guidelines, Activities and Interventions; and Monitoring of Appropriate 
Use. The indicators were rated for feasibility, clinical importance and relevance to minimizing 
antimicrobial resistance. Three rounds of rating followed by the in-person meeting led to a final set of 
33 indicators. Among them 17 indicators were considered essential to characterize an ASP and therefore 
were included in a core set of indicators. The remaining 16 indicators were considered optional 
indicators and included in a supplemental set. 
Implementation of the TATFAR-developed core indicators in multiple nations would contribute to a 
comprehensive, comparative description of infrastructure, policies, and practices of ASPs 
internationally. These findings could, in turn, lead to an understanding of best practices of ASPs through 
further investigation into the relation of different ASP approaches to antimicrobial use and resistance. 
Current public health surveillance systems or special studies may also be candidates for the addition of 
ASP questions to baseline surveys. Furthermore these indicators are envisaged as drivers for 
improvement and alignment with adoption of best practices. Piloting, implementation and evaluation of 








The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) was established in 2009 following a 
European Union-United States (EU-US) summit declaration that acknowledged the growing global threat 
of antimicrobial resistance (AMR). The initial goal of TATFAR was to define specific areas where enhanced 
cooperation between EU civil servants and US government employees, with input from invited non-
governmental expert consultants, could have the most significant impact on addressing AMR. Three key 
areas were identified: 1) appropriate therapeutic use of antimicrobial drugs in the medical and veterinary 
communities; 2) prevention of both healthcare and community-associated drug-resistant infections; 3) 
strategies for improving the development of new antimicrobial drugs. A set of 17 recommendations to be 
met through formal collaboration was adopted in September 2011 (Annex A).[1]  
 
TATFAR Recommendation 1: Develop structure and process indicators for 
hospital antimicrobial stewardship programs 
The first TATFAR recommendation focuses on supporting appropriate use of antimicrobial drugs in 
human medicine through antimicrobial stewardship programs (ASPs). A workgroup coordinated by 
European Centre for Disease Prevention and Control (ECDC) and the US Centers for Disease Control and 
Prevention (CDC) was charged to develop common structure and process indicators for hospital ASPs 
(TATFAR recommendation 1). Common indicators that are feasible and relevant to both EU Member 
States and US would allow for meaningful characterization and comparisons of antimicrobial 
stewardship efforts among different nations and healthcare systems. Antimicrobial stewardship refers 
to a coordinated program that implements interventions to ensure appropriate antimicrobial prescribing 
to improve clinical efficacy of antimicrobial treatment, to limit AMR and to prevent Clostridium difficile 
infections. Antimicrobial stewardship contributes to high quality and effective healthcare through 
decreasing unnecessary antimicrobial-related morbidity and mortality and limiting selective pressure to 
minimize development of resistance to currently effective antibiotics.  
 
Indicators are measures that are used to monitor and assess the quality of a particular healthcare process. 
Such indicators evaluate the organizational aspects of the process, including material and human 
resources (structural indicators), the actual care provided (process indicators) and the effects of the 







 In March 2014, workgroup members began regular meetings to develop a manageable set of indicators 
that would describe the structure and functions of ASPs across a variety of healthcare systems  Relevant 
stakeholders representing hospitals with various levels of ASP infrastructure, experience  provided their 
expert opinion to  build upon previous and ongoing stewardship indicators work in the EU and the US.  
 
Objectives  
The objective of the project was to develop a set of structure and process indicators for hospital ASPs that 
would be evidence-based and applicable to both the EU member states and the US and that would 
promote effective antimicrobial stewardship activities and allow comparisons at international levels. 
Methodology 
Developing a set of process and structure indicators 
An initial list of indicators was developed through a review of previously developed structure and process 
indicators, antimicrobial stewardship surveys and guidelines in the EU and US.[3-8] Indicators assessing 
all domains of ASPs were included in the initial list. These domains were: Governance and Management; 
Human Resources; Laboratory; Information Technology; Education; Policies for Appropriate Use; 
Guidelines, Activities and Interventions; and Monitoring of Appropriate Use. The proposed indicators 
were derived from the Cochrane systematic review of interventions to improve antimicrobial prescribing 
practices for hospital patients by Davey et al.[9], as well as a review of studies published from 2006 to 
2013 A modified Delphi method was utilized as a structured consensus method to facilitate equal expert 
participation and collaboration, as well as to make this international collaboration logistically feasible.[10] 
The rating criteria considered relevant for the purpose of development of common indicators that would 
make sense in very different settings were: feasibility, clinical importance and relevance to minimization 
of resistance. These chosen criteria drew on the practical experience of the invited experts, most of whom 
lead antimicrobial stewardship efforts in clinical settings. Moreover, due to the large variability of the 
systems in terms of both infrastructure and activities between and within the EU and the US, we aimed 
at two sets of indicators: a “core” set, including indicators that would be considered essential and 
necessary to characterize an ASP, and a “supplemental” set of optional indicators, that may be chosen 






over a period of three months between March and May 2014. All rounds were completed online using 
Microsoft Word documents and email. Participants received feedback via email. Two group calls with 
members of the expert panels and a trained CDC moderator took place after Round 2 was complete. A 
group consensus meeting took place after the conclusion of Round 3 at the end of the modified Delphi 
process.  
The modified Delphi expert panel 
A multidisciplinary group of EU and US experts were recruited to participate in the modified Delphi 
process. Purposive sampling was used to ensure that those asked to participate had the necessary 
expertise and experience for the development of the indicators, knowledge about clinical and/or public 
health practice, and could represent diversity in geography and healthcare systems. Participants in the 
expert panel were selected by ECDC and CDC based upon expertise and willingness to participate in the 
entire process. European experts were selected to participate by ECDC and US experts were selected to 
participate by CDC. Experts selected were sent letters of invitation to participate in the modified Delphi 
process via email. All 20 experts invited to participate accepted the invitation, with representation from 
nine EU member states and six US states; two of the participants on the expert panel also served as 
ECDC/CDC coordinators for the project (DP and LP).  
 
The modified Delphi rounds 
First Round 
The initial list consisted of 53 indicators based on previous process and structure indicators used in the 
EU and the US. The goal of the first round was to make the list of proposed indicators more focused and 
manageable for the rating in Rounds 2 and 3. Participants were asked to either “Retain” or “Remove” 
indicators based on their ability and feasibility to characterize ASPs. Participants were also encouraged to 
propose modifications and additional indicators during this first round of the modified Delphi process. 
Responses were summated for total “Retain” and total “Remove” ratings. The denominator was adjusted 
for non-responses. Based on the median results, a 60.0% “Retain” cut-off was used to determine the 
retention of an indicator for the next round. Additional notes, comments, and revisions suggested by 
experts were reviewed for all indicators. For indicators which did not meet the retention cutoff, notes, 








There were 44 indicators carried forward to Round 2. Participants were asked to rate each of the structure 
and process indicators on a Likert scale from 1 to 9 according to the three criteria on domains of Feasibility 
(i.e., it would be possible to implement and measure this indicator at a facility level); Clinical Importance 
(i.e., this indicator is important to optimizing the appropriateness of antimicrobial prescribing); and 
Relevance to Minimizing AMR (i.e., this indicator is relevant to reducing the development of antimicrobial 
resistance), where 1 indicates ‘Strongly Disagree’ and 9 indicates ‘Strongly Agree’ for the three domain 
criteria. Participants were also asked for any additional comments, and suggestions.  
 
Median, mean, minimum and maximum ranges were determined for each item. The denominator was 
adjusted for non-responses. Additional notes, comments, and revisions suggested by experts were 
reviewed for all indicators to determine possible revision and retention into the next round. For each 
indicator, an overall median score was created from summations of the medians for feasibility, clinical 
importance, and relevance to minimizing AMR for each indicator. Because of low scores in the relevance 
to minimizing AMR domain, indicating lack of evidence for an effect of ASPs on antimicrobial resistance a 
modified median score was also determined as the sum of the medians for only feasibility and clinical 
importance for each indicator (Possible range 2-18).  
 
Panel agreement was measured using the interpercentile range adjusted for symmetry (IPRAS) 
agreement score described in RAND/UCLA appropriateness method.[11] Instead of using RAND/UCLA 
70/30 interpercentile range (IPR), a 90/10 IPR was used for better discriminating power. Based on the 
modified median scores for feasibility and clinical importance, a cut off of 14 was determined as the 
threshold for retaining an indicator, corresponding to individual indicators with median ratings in the 
upper third of the Likert scale (7-9). Participants were provided feedback on the aggregate, compiled 
responses and asked to participate in a group call to further discuss indicators with borderline scores 








After Round 2 was complete and participants had received feedback, a group conference call to discuss 
questions, comments, and concerns related to the rating process was offered twice to maximize 
participation by accommodating the experts’ schedules. A CDC behavioral scientist trained in group 
facilitation (RS) moderated both calls using the same semi-structured script to facilitate discussion. The 
one-hour call began with an overview of the scope and purpose of the TATFAR project. Questions and 
logistical information regarding the next round of input and the in-person meeting were addressed. 
Participants were given an overview of the methodology used during the second round including an 
overview on the RAND/UCLA appropriateness methods for the IPRAS score. Indicators with low 
agreement (IPRAS-IPR = 0-2) or disagreement (IPRAS < IPR) for the same indicator, borderline modified 
median scores (12-14) and modified median scores >14 with median ratings for clinical importance <7 
were further discussed at the group call.   
 
Third Round 
In the third and final round, participants were asked to rate the remaining 38 structure and process 
indicators according to the two criteria below on a Likert scale from 1 (Strongly Disagree) to 9 (Strongly 
Agree) on the domains of Feasibility and Clinical importance. Participants were also asked to rate the 
necessity of each item (i.e., This indicator should be included as either a Core or Supplemental indicator, 
or removed).  
 
Median, mean, minimum and maximum ranges were determined for each item. The denominator was 
adjusted for non-responses. An overall median score was created from summations of the individual 
medians for feasibility and clinical importance (possible range 2-18). The change in median scores (delta) 
from Round 2 to Round 3 was calculated for each indicator. The necessity ratings were presented as 
percentages of the participants who rated each indicator as Core, Supplemental, or Remove. Two options, 
“strict” and “liberal”, were used to suggest cutoff points for including the indicator as Core, Supplemental, 







Strict criteria: If the remove "X" percentage was ≥ 20.0%, then the indicator was removed. If core 
“C” percentage was ≥ 70.0%, then that indicator was retained as a Core Indicator. The remaining 
indicators were retained as a Supplemental Indicators.  
Liberal criteria: If the remove "X" percentage was ≥ 20.0%, then the indicator was removed, unless 
the supplemental "S" percentage was >=50% for the same indicator, then that indicator was 
retained as supplemental. If the core “C” percentage was ≥ 50.0%, then that indicator was kept 
as a Core Indicator. The remaining indicators were retained as a Supplemental Indicators. 
 
Additional notes, comments, and revisions suggested by experts were reviewed for all indicators to 
determine possible revision and retention. Final decisions regarding classification of indicators were made 
by consensus at the in-person meeting. 
 
The consensus meeting: Defining a final set of process and structure indicators 
On June 18, 2014, an in-person meeting was held to review the ratings, expand upon comments from 
the previous rounds of input and collaboratively determine inclusion of indicators as Core and 
Supplemental. Thirteen of the experts who participated in the modified Delphi process (65%), 
representing nine countries attended; those who could not were forwarded the outcomes as a draft 
final report for comment. After briefly reviewing the background and goals of TATFAR, participants were 
reminded the objective was to develop a manageable number of indicators that could characterize and 
differentiate among ASPs, integrate with other assessment tools and be compared among different 
healthcare systems. The project coordinators (DP from ECDC and LP for CDC) facilitated a guided 
discussion informed by the results of the final round of input, the strict and liberal criteria for inclusion, 
and comments from all previous rounds to achieve consensus on the remaining 38 indictors being 
classified as Core or Supplemental, or be removed.  
Results 
First round  
In Round 1 of the modified Delphi Process, participants were asked to choose to “Retain” or “Remove” 53 
proposed structure and process indicators. There was a 100% response rate (20/20) from the expert 






Experts noted that proposed indicators were mostly focused on ASP staffing and activities (structure), but 
did not capture the extent of activity performance (process). In response, eight process indicators were 
added to the second round of rating (e.g., Does your facility measure the number of antimicrobial 
prescriptions that are consistent with the local treatment recommendations? If YES, are antimicrobial 
prescriptions compliant with facility-specific guidelines in >95% of sampled cases in your facility?). The 
threshold of 95% was chosen based on current indicators at national level. In response to comments, two 
separate indicators asking if there is an infection preventionist and a hospital epidemiologist on the 
stewardship team were merged together. Table 2 summarizes the results of Round 1.  
 
Second round  
The response rate for Round 2 was 95% (19/20). The overall median score for feasibility, clinical 
importance, and relevance to resistance was 7.0, 8.0, 6.0, respectively (Table 3). Indicators related to 
cumulative susceptibility reports and guidelines were rated high for both feasibility and clinical 
importance; whereas those related to governance and management of ASPs and policies were rated 
higher for feasibility than clinical importance, and indicators related to ASP activities were rated higher 
for clinical importance than feasibility. For relevance to minimizing AMR, no indicator had a median score 
higher than 7 (on a 1-9 Likert scale) and there was low agreement on the scoring of relevance to 
minimizing AMR among the experts. Given the low scores and high disagreement, rating of relevance to 
minimizing AMR was not repeated in the final round. An overall modified median score was calculated by 
suming the median scores for feasibility and clinical importance and excluding relevance to minimizing 
AMR(Possible range 12-18). The median, mean, range, and overall median scores for each indicator were 
provided to all experts prior to a group call.  
 
Fourteen (70%) experts participated in either one of two group calls to discuss divergent responses and 
comment on the proposed indicators. The first call had representation from seven EU countries and three 
US states and the second call had representation from one EU country and two US states. After an 
introduction and overview of the methods and results from Round 2, the discussion began with 
clarification of the “feasibility” rating, which may have been operationalized differently by raters. 
Participants remarked that agreement or disagreement in feasibility ratings might be related to 
differences in healthcare settings and systems more than to discordant expert opinion. The domain of 






equipment, electronic systems) led to discussion on whether or not to remove the IT indicators or refocus 
the domain in more general terms. Some experts expressed that IT indicators are drivers for improvement 
and should be retained to track growth in the future, even if all nations or systems may not yet have 
advanced IT capacity for ASPs. Feedback was sought on the measurement indicators, Days of Therapy 
(DOT) and by Defined Daily Dose (DDD). Because DDD is used in the European Union and DOT is used in 
the US, experts recommended combining these two indicators into a single indicator and asking about 
use of  either one of these metrics.  
 
After analysis of the Round 2 ratings and input from the expert group calls, 37 of the 44 proposed structure 
and process indicators were retained (26 as proposed and 11 with minor revisions)(Table 5). An indicator 
that previously combined assessment of compliance with community-acquired pneumonia (CAP) and 
urinary tract infection (UTI) guidelines was divided into two separate indicators, making a total of 38 
indicators advancing to Round 3. The following indicators were removed: two human resources indicators 
(involvement of IT staff and quality improvement staff); two indicators related to IT (presence of an IT 
system for prescribing and its application to clinical decision support for antimicrobial prescribing); the 
indicator on routine use of antimicrobial order forms and the indicator about dedicated time for clinical 
teams to review antimicrobial orders. For the proposed process indicators 95% threshold was replaced by 
80% after the experts indicated that the former threshold was not practical. 
 
Third round 
The response rate for the third round was 95% (19/20 experts). The average median scores for feasibility 
and clinical importance were 7.5 (6-9) and 7.8 (6-9), respectively. The average combined median score for 
feasibility and clinical importance was 15.0 (5-18). A summary of the Round 3 results are presented in 
Table 6. The indicators with highest agreement for feasibility among participants (as determined by IPRAS 
score) were the identification of a defined ASP, formulary, and surgical prophylaxis guidelines; whereas 
the indicators with lowest agreement on feasibility were process indicators that assessed if “>80% of 
sampled cases” had a documented indication or followed facility-specific guidelines (Table 7). For clinical 
importance, the indicators on physician and pharmacist leadership, information technology capability, 
facility-specific treatment guidelines, and post-prescription review and feedback had high agreement in 






discontinuation of specified antimicrobial prescriptions after a pre-defined duration, and the capture of 
indication for treatment in the medical record had the lowest agreement scores.  
 
Using the strict criteria based on the percent of experts rating the necessity of an indicator as “Core”, 
“Supplemental” or to “Remove”, 7 indicators would be considered Core indicators, 21 indicators would 
be Supplemental, and 9 indicators would be removed (Table 8). The core indicators under the strict criteria 
were: 
1. Does your facility have a formally defined antimicrobial stewardship program for ensuring 
appropriate antimicrobial use? (78.9% experts rated this as a Core indicator) 
2. Is an antimicrobial stewardship team available at your facility? (83.3%) 
3. Is there a physician identified as a leader for stewardship activities at your facility (88.9%)  
4. Is there a pharmacist responsible for working to improve antimicrobial use at your facility? 
(76.5%) 
5. Does your facility produce a cumulative antimicrobial susceptibility report at least annually? 
(73.7%) 
6. Is there a formal procedure for a physician, pharmacist, or other staff member to review the 
appropriateness of an antimicrobial after 48 hours from the initial order (post-prescription 
review)? (72.2%) 
7. Does your facility monitor antimicrobial use by grams [Defined Daily Dose (DDD)] or counts [Days 
of Therapy (DOT)] of antimicrobial(s) by patients per day? (89.5%) 
 
Most of the indicators that were contingency questions (i.e., If YES,...) met the strict criteria to be 
removed. Using the liberal criteria, 14 Core and 22 Supplemental indicators would be retained and 2 
indicators would be removed (Table 8). 
Expert consensus meeting following third round 
At the final in-person meeting, the 13 experts in attendance were presented the above seven indicators 
which were deemed to be Core Indicators by ≥ 70.0% of participants in the third round of rating. There 
was consensus that these indicators should be Core Indicators in the assessment of hospital ASPs, with 
minor revisions to clarify definitions and capture accountability of stewardship efforts.  
 
The moderators focused attention first on indicators that >20% of the experts recommended for 
removal in the third round of input. A majority of experts at the meeting recommended removal of the 






facility-specific CAP and UTI guidelines for the following reasons: disagreement on feasibility; collection 
of such data would increase workload; accurate quantification would be challenging; and the indicator 
may not reflect appropriateness of non-guideline concordant clinical decisions. Similarly, documentation 
of an indication for treatment in “>80% of sampled cases” was rejected. Some experts noted that 
monitoring other aspects of prescribing antimicrobials may be a more effective use of ASP time than 
attempting to quantify the compliance. In contrast to not recommending the assessment of compliance 
with CAP and UTI, monitoring of surgical prophylaxis as a Core indicator was strongly advocated for by 
EU participants. The feasibility of this indicator is supported by the fact it is already being measured in 
the US through Surgical Care Improvement Project measures.[12, 13] Therefore, the group 
recommended that audit or review of surgical prophylaxis choice and duration be reclassified from a 
Supplemental to a Core indicator and the quantification of guideline-concordant surgical prophylaxis 
becomes a Supplemental indicator. A majority of the experts recommended two more indicators for 
removal: 1) “a current susceptibility report has been distributed to prescribers” because this indicator 
does not assess the application of this information to patient care nor the ability of prescribers to 
interpret it; and 2) “does your facility have a defined formulary of antimicrobial agents?” because the 
term formulary was found to have different interpretations and diversity in prescribing may be 
considered an approach to prevention of antimicrobial resistance.[14-16] 
 
The remaining indicators, those which were neither deemed Core nor removed at this point in the 
meeting, were presented and the expert group was asked to identify and discuss whether any of these 
indicators should be added to the Core Indicator list. Themes that emerged were necessity of support 
and accountability for stewardship activities, therefore questions related to an organizational structure 
responsible for antimicrobial stewardship, salary or dedicated time, and information technology support 
of activities were classified as Core. Core indicator 6 specified salary support to differentiate a higher 
level of support than mere inclusion of ASP responsibilities in job duties (i.e., Supplemental indicator 5) 
without salary support. When discussing an “antimicrobial stewardship team”, experts’ input reflected 
the importance of coordinated efforts of multidisciplinary staff, but also acknowledged that the specific 
composition of teams was highly variable by healthcare systems and among facilities within the same 
system. Therefore, indicators that asked about specific staff roles were retained as Supplemental rather 
than becoming Core indicators. Policies and practices added as Core indicators were: a general question 
on the presence of facility-specific treatment recommendations (recommendations for specific clinical 






of an indication coupled with monitoring of that policy, however experts did not endorse setting a 
threshold (e.g., >80% compliance); and pre-authorization of specified antimicrobial agents. Two 
indicators related to monitoring and feedback were moved to Core indicators: 1) review of surgical 
prophylaxis as discussed earlier; and 2) direct communication of antimicrobial audits or reviews to 
prescribers. Active feedback was felt to be more effective in changing prescribing practices compared to 
passive education of prescribers, which was therefore not included in the final indicator list. An annual 
report on antimicrobial stewardship was also included as a Core indicator as a marker of overall 
organization and function of the ASP. The annual report indicator and the indicator related to 
information technology capability were seen as “reach” goals – indicators that may be advanced for the 
current state of ASPs in a majority of facilities but important to differentiate ASPs and set a target for 
advanced achievement. Altogether, after the discussion, ten more indicators were added to the seven 
indicators identified as Core at the start of the meeting. At the conclusion of the in-person meeting, 









Final set of Core and Supplemental indicators for hospital antimicrobial 
stewardship programs 









1. Does your facility have a formal antimicrobial stewardship program accountable for 
ensuring appropriate antimicrobial use?  
2. Does your facility have a formal organizational structure responsible for antimicrobial 
stewardship (e.g., a multidisciplinary committee focused on appropriate antimicrobial use, 
pharmacy committee, patient safety committee or other relevant structure)?  
3. Is an antimicrobial stewardship team available at your facility (e.g., greater than one staff 
member supporting clinical decisions to ensure appropriate antimicrobial use)?  
4. Is there a physician identified as a leader for antimicrobial stewardship activities at your 
facility? 
5. Is there a pharmacist responsible for ensuring appropriate antimicrobial use at your facility? 
6. Does your facility provide any salary support for dedicated time for antimicrobial 
stewardship activities (e.g., percentage of full-time equivalent (FTE) for ensuring appropriate 
antimicrobial use)? 











8. Does your facility have facility-specific treatment recommendations based on local 
antimicrobial susceptibility to assist with antimicrobial selection for common clinical 
conditions? 
9. Does your facility have a written policy that requires prescribers to document an indication 
in the medical record or during order entry for all antimicrobial prescriptions? 
10. Is it routine practice for specified antimicrobial agents to be approved by a physician or 
pharmacist in your facility (e.g., pre-authorization)? 
11. Is there a formal procedure for a physician, pharmacist, or other staff member to review the 














12. Has your facility produced a cumulative antimicrobial susceptibility report in the past year? 
13. Does your facility monitor if the indication is captured in the medical record for all 
antimicrobial prescriptions? 
14. Does your facility audit or review surgical antimicrobial prophylaxis choice and duration? 
15. Are results of antimicrobial audits or reviews communicated directly with prescribers?  
16. Does your facility monitor antimicrobial use by grams [Defined Daily Dose (DDD)] or counts 
[Days of Therapy (DOT)] of antimicrobial(s) by patients per days? 
17. Has an annual report focused on antimicrobial stewardship (summary antimicrobial use 
















S1. Does your facility have a named senior executive officer with accountability for antimicrobial 
leadership? 
 
(Core 3) Is an antimicrobial stewardship team available at your facility (e.g., greater than one staff 
member supporting clinical decisions to ensure appropriate antimicrobial use)? 
S2.  If YES, Is an infection preventionist or hospital epidemiologist involved in stewardship 
activities? 
S3.  If YES, Is a microbiologist (laboratory staff) involved in stewardship activities? 
S4. Is clinical infectious disease (ID) consultation available at your facility? 
 
(Core 4) Is there a physician identified as a leader for antimicrobial stewardship activities at your 
facility? 
S5. If YES, are stewardship duties included in the job description and/or annual review? 
S6. If YES, has this physician had specialized training in infectious diseases, clinical microbiology 
and/or antimicrobial stewardship? 
 
(Core 5) Is there a pharmacist responsible for ensuring antimicrobial use at your facility? 












(Core 9) Does your facility have facility-specific treatment recommendations based on local 
antimicrobial susceptibility to assist with antimicrobial selection for common clinical conditions: 
S8. If YES, for surgical prophylaxis? 
S9. If YES, for community-acquired pneumonia? 
S10. If YES, for urinary tract infection? 
S11. If YES to any of the clinical conditions above, are these treatment recommendations easily 
 accessible to prescribers on all wards (printed ‘pocket guide’ or electronic summaries at 
 workstations)? 
 
(Core 11,12) Are any of the following actions implemented in your facility to improve antimicrobial 
prescribing? 
S12. Standardized criteria for changing from intravenous to oral antimicrobial therapy in 
appropriate situations? 
S13. Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the treatment of 
 organisms with reduced susceptibility? 








S15. Does your facility measure the percentage of antimicrobial prescriptions that are consistent 
with the local treatment recommendations for either UTI or CAP? 
 
(Core 15) Does your facility audit or review surgical antimicrobial prophylaxis choice and duration? 
S16. If YES, are antimicrobial prescriptions for surgical prophylaxis compliant with facility-







Summary: Response to TATFAR Recommendation 1 
Based on available evidence, standardized methodology, and professional experience, an international 
group of experts in antimicrobial stewardship developed a set of core and supplemental indicators to 
characterize the infrastructure and activities of hospital ASPs. The final set of 17 core and 16 
supplemental indicators reflects the input and agreement of clinical and public health professionals with 
diverse perspectives and experiences in antimicrobial stewardship and indicator development. This 
activity addresses the TATFAR recommendation to develop common structure and process indicators for 
hospital ASPs. It also achieves intangible TATFAR goals of increased EU-US awareness of activities and 
capabilities to address antimicrobial resistance and an exchange of ideas and best practices in 
antimicrobial stewardship.   
 
Comparison to previously developed ASP assessments  
The selection of candidate indicators built upon the development and implementation of similar efforts 
to assess the ASP organization and activities in the hospital setting. In France, a standardized 
questionnaire has been used to assess antibiotic policy in hospitals at the national level since 2006 and 
was updated in 2013. Annual reporting from individual facilities to the Ministry of Health has been 
mandated since 2007, from which a composite score for antibiotic policies (“ICATB” indicator) based on 
13 questions is calculated for public reporting and ASP evaluation.[17]  To take into account progress 
made and identification of new key elements for ASP in the French context, an updated version of ICATB 
indicator is being used in 2014, comprising 27 questions to calculate a score reflecting ASP 
implementation. Analysis of this data has been able to show the growth in ASPs and the association of 
antibiotic policy and antibiotic consumption.[5, 18] In 2006, the European Commission sponsored the 
Antibiotic Strategy International project to develop and pilot ASP structure indicators in four European 
Union countries. This project identified 58 indicators, including 10 key structure indicators, to assess the 
activities and capacity of ASPs.[3] The UK has had an Antimicrobial Stewardship Subgroup as part of the 
Antimicrobial Resistance and Healthcare-Associated Infection Advisory Committee since 2003.[19] In 
2010, an Antimicrobial Stewardship Self Assessments Tool (ASAT) became available online followed by 
the dissemination of ASP guidance for primary care and hospitals entitled Start Smart, Then Focus in 
2011. [6, 19] The tool asks a series of questions on antimicrobial management, policies, practices and 
education, which are given a weighted scoring. This allows Trusts to identify areas for improvement or 






Trusts in the UK and is currently being redeveloped for easier access via a web portal. In Germany where 
a formal hospital ASP training program started in 2010 a recently released national guideline for hospital 
ASP recommends to use at least 3 structural and 3 process of care quality indicators out of list of 21 
structural and 21 process of care indicators that were evaluated and agreed upon among a large panel 
of hospital physicians and pharmacists having completed the ASP training.[20, 21] In the US, there have 
been surveys on ASPs conducted by some state health departments and large healthcare systems. [22-
25] These efforts provided insight into stewardship infrastructure and practices, but were not 
comparable. To support a more standardized assessment, CDC released a checklist of core elements for 
hospital ASPs in 2014.[26] 
 
Experts that were involved in the development, implementation, and analysis of many of these ASP 
assessment efforts contributed greatly to the TATFAR indicators by sharing their experience regarding 
which indicators were most feasible, useful, and applicable to ASP evaluation. By design, the TATFAR 
core indicators are a smaller number of items that correspond with each of these efforts such that items 
on previously developed and implemented assessment tools could be analyzed, shared, and compared. 
There are similarities and differences among these tools that were developed individually, but share a 
common goal of measuring ASPs in hospital settings. A comparison of the TATFAR antimicrobial 
stewardship indicators to previously developed indicators are summarized in Tables 9 and 10. 
 
Potential for implementation  
Implementation of the TATFAR-developed core indicators in multiple nations would contribute to a 
comprehensive, comparative description of infrastructure, policies, and practices of ASPs 
internationally. These findings could, in turn, lead to an understanding of best practices of ASPs through 
further investigation into the relation of different ASP approaches to antimicrobial use and resistance. 
Current public health surveillance systems or special studies that may be candidates for the addition of 
ASP questions to baseline surveys are the European Surveillance of Antimicrobial Consumption Network 
(ESAC-Net) administered by ECDC, the National Healthcare Safety Network (NHSN) administered by the 
US CDC , or point prevalence surveys of antimicrobial use done by both ECDC and CDC. At the national 
or state level the indicators could be incorporated into surveys such as the aforementioned assessments 
in EU member states, or assessments of facilities within large health systems within the US, such as the 






of this task, the specific wording of indicators may require modification to be best understood, relevant, 
and align with currently administered assessments. There will be a need to balance flexibility versus 
consistency in definitions of the indicators and to accept the similar indicators that are used in existing 
surveys. Instructions on the target audience of respondents intended to complete the assessment along 
with accompanying interpretive guidance should be given to ensure proper administration and valid 
responses by each country willing to use these indicators. To prove the validity, reliability, and feasibility 
of these TATFAR indicators, a multi-site demonstration project at country or multi-state level under the 
auspices of TATFAR is a needed next step to confirm applicability and further refine the indicators. In 
addition, countries and systems that are interested in comparing data can collaborate on a protocol to 
share data, align timelines, and plan analyses. 
 
Strengths and limitations 
The modified Delphi process to solicit input on the feasibility and clinical importance of each proposed 
indicators ensured equal representation among the expert group members. The strengths of this 
approach are that it is a widely used, standardized method in healthcare quality indicator development 
that allows for input and collective consensus across diverse geographic locations. Participants in the 
expert group were provided feedback after each round and given the opportunity for meaningful 
exchange on the interpretation and reasoning of each other’s responses. Potential limitations were that 
all rating rounds and meetings were conducted in English which may have created a cultural bias or 
limited the participation of those who did not feel most comfortable exchanging views in English. In 
addition, the self-reported responses could be biased to personal and/or institutional experience. 
However, expert input based on experience in the field of AS is informative  where there is limited high-
quality evidence and results are difficult to interpret and extrapolate. In addition, the in-person meeting 
contributed greatly to developing a common understanding and reaching final consensus. Although the 
final meeting at which key decisions were made did not include all participants and judgments from the 
group in attendance may not have been representative of the entire group, all experts were given an 
opportunity to review and comment on the outcome of the meeting. Finally, the literature review 
informing the initial selection of indicators was not exhaustive and was highly dependent on a 
systematic review which was being updated at the time. The evidence base for individual indicators is 






structure) to activities and ultimately outcomes, because most stewardship interventions reported in 
the literature are multifaceted and involve a combination of clinical practice factors to attain results.  
 
 
Strengths of the process were that the highly convergent scores reflected consensus among the expert 
group and the focus on feasibility and clinical importance of each indicator ensured that the final 
indicators are likely to be practical in diverse settings and meaningful to quality of care. In addition, 
there were multiple opportunities for clarification and revision through the reiterative process of rating 
and soliciting comments. A majority of the final indicators are structure rather than process indicators, 
which we believe reflects both the critical importance of staffing, baseline capacity, and support for 
ASPs as well as the early stage of ASP implementation in healthcare. Although some experts expressed 
that specific measurements of adherence (e.g., what percent of antimicrobial prescriptions are 
compliant with facility-specific guidelines?) may not be feasible or the most efficient use of antimicrobial 
stewardship team time, some institutions have successfully implemented such measures,[27] thus such 
indicators may become more feasible and relevant as ASPs advance.  
 
Ensuring appropriate antimicrobial use is recognized as a key strategy to addressing antimicrobial 
resistance and a primary goal of TATFAR. In the modified Delphi process, ratings on relevance to 
minimizing AMR among the experts were highly divergent and reflected that, although individual 
indicators may impact antimicrobial resistance in certain settings, the research evidence on the impact 
of many of the proposed indicators on minimizing AMR is sparse. Establishing the relationship of ASPs 
and interventions on antimicrobial resistance is challenging because, in addition to selective pressure, 
other factors, such as underlying resistance in the community and transmission among patients, impact 
the development of resistance. The time lag and relationship of changes in hospital antimicrobial use to 
resistance patterns are inconsistent and not recommended to reliably evaluate ASP interventions.[28] 
There are, however, other markers of ASP success. Measurement of antimicrobial use along with other 
patient-focused outcomes is critical to demonstrate impact of ASPs and should be considered. Outcome 
indicators for ASPs were not evaluated as part of this project because establishment of standards for 








The Core and Supplemental indicators developed through a modified Delphi process represent features 
of ASPs that a multinational group of highly experienced experts deemed to be essential elements to 
ensuring appropriate use of antimicrobials in the hospital setting. The collaborative development of 
these indicators for TATFAR contributed to mutual understanding of the capacity and vision for hospital 
ASPs in member states of the EU and the US.   Future directions to advance the field include integration 
of prescribing practice improvement into infection control, fostering accountability for both facilities 
and prescribers, and understanding behavioral factors that influence prescribing practices.   A better 
understanding of effective ASP practices will stimulate replication or adaption of successful 
interventions from one setting into another, including across the continuum of care into outpatient and 
long-term care settings.  The selection and recommendation of structure and process indicators 
contributed to defining clear expectations for hospital ASPs, but will not directly impact practice without 
continued refinement through piloting, implementation and, eventually, formal evaluation of impact on 









A. TATFAR recommendations for future collaboration between the EU 







B. Rating Criteria for Second and Third Rounds 
 
Feasibility: It would be possible to implement and measure this indicator at a facility level. 
1 = Strongly disagree (cannot be implemented and measured regardless of resources available)  
5= Neutral (not certain this can be implemented and measured, increase in available resources 
would be needed) 
9 = Strongly agree (definitely feasible, this can be implemented and measured with resources 
presently available) 
 
Clinical importance: This indicator is important to optimising the appropriateness of antimicrobial 
prescribing. 
1 = Strongly disagree (unlikely to have impact on appropriate prescribing, basic research 
needed) 
5= Neutral (potential impact on a majority of patients, indeterminable research evidence 
available) 
9 = Strongly agree (potential for widespread impact, confident about effectiveness, no further 
research needed) 
 
Relevance to minimizing resistance: This indicator is relevant to reducing the development of 
antimicrobial resistance. 
1 = Strongly disagree (unlikely to have an impact on reducing antimicrobial resistance, basic 
research needed) 
5= Neutral (may impact on resistance in a certain settings, indeterminable research evidence 
available) 










C. Summary of results for modified Delphi process rounds  
Table 1. Round 1 Results: Remove or Retain 
 
No Indicator Retain  % Result 
 Structure indicators    
 Governance and management    
1 Does your facil ity have a formal mandate for ensuring appropriate 
antimicrobial use (antimicrobial stewardship)? 
14 70.0 Retain 
2 Does your facil ity have a multidisciplinary committee focused on appropriate 
antimicrobial use? (e.g., antimicrobials stewardship team) 
17 85.0 Retain 
3     If YES, Does this stewardship team meet regularly (at least twice a year)? 8 40.0 Remove 
4    If YES, Are minutes from the stewardship team meetings sent to executive 
leadership? 
8 40.0 Remove 
5 Has an annual report focused on antimicrobial stewardship (summary 
antimicrobial use and/or practices improvement initiatives) been produced 
for your facil ity in the past year? 
16 80.0 Retain 
6 Does your facil ity receive any budgeted financial support for antibiotic 
stewardship activities (e.g., support for salary, training, or IT support)? 
17 85.0 Retain 
 Human Resources    
7 Is cl inical infectious disease (ID) consultation available at your facil ity? 14 70.0 Retain 
8 Is a full-time pharmacist available on site at your facil ity? 11 55.0 Remove 
9 Does your facil ity perform the majority of its microbiology testing on site? 7 35.0 Remove 
10 Is there a physician identified as a leader for stewardship activities at your 
facil ity? 
20 100.0 Retain 
11    If YES, does this physician receive any direct salary support for this role? 15 75.0 Retain 
12    If YES, Is this physician trained in infectious diseases? 13 68.4 Retain 
13 Is there a pharmacist leader responsible for working to improve antibiotic use 
at your facil ity? 
16 80.0 Retain 
14   If YES, are stewardship duties included in the job description and/or annual 
review? 
11 55.0 Remove 
15   If YES, has the lead pharmacist had specialized training in infectious disease 
management or stewardship? 
12 60.0 Retain 
 Are any of the staff below members of the stewardship team at your facil ity?    
16 Microbiologist (Laboratory) 15 79.0 Retain 
17 Infection preventionist 14 75.0 Retain 
18 Hospital epidemiologist 10 60.0 Remove 
(merged 
with 17) 
19 Information Technology (IT) staff member 13 70.0 Retain 
 Laboratory    
20 Does your facil ity produce an antibiogram (cumulative antimicrobial 
susceptibility report) at least annually? 
19 95.0 Retain 










 Information Technology    
 Which of the following information technology (IT) systems are currently 
available and used in your facil ity: 
   
22 Electronic medical or health record? 10 50.0 Remove 
No Indicator Retain  % Result 
23 IT system for prescribing (Computerized Order Entry)? 15 75.0 Retain 
24 IT system for medication dispensing or administration? 8 40.0 Remove 
25 IT capability to electronically l ink pharmacy, laboratory, and medical records? 13 65.0 Retain 
26 Does the computer order entry system support clinical decision making for 
prescribing antimicrobial agents? 
14 70.0 Retain 
 Education    
27 Has your facil ity given an educational presentation on improving antibiotic 
prescribing within the last year? 
11 55.0 Remove 
28 Do prescribers ever receive direct, personalized communication about how 
they can improve their antibiotic prescribing? 
17 85.0 Retain 
29 Has a current antibiogram been distributed to prescribers at your facil ity in 
the last year? 
14 73.7 Retain 
30 Does your facil ity have a training strategy to promote appropriate 
antimicrobial use? 
11 55.0 Remove 
31 Are patients or their legal guardian routinely given information about 
antimicrobials they have received (indication, course length, possible risks, 
what to do if side effects develop at home etc.)? 
3 15.0 Remove 
 Process indicators    
 Policies for appropriate use    
32 Does your facil ity have a defined formulary of antimicrobial agents? 16 80.0 Retain 
33 Is there a written policy for approval of new antimicrobial agents onto the 
formulary? 
5 26.3 Remove 
34 Does your facil ity have a written policy that requires prescribers to document 
in the medical record or during order entry a dose, duration, and indication 
for all  antibiotic prescriptions? 
18 90.0 Retain 
 Guidelines    
 Does your facil ity have facil ity-specific treatment recommendations, based on 
national guidelines and local susceptibility, to assist with antibiotic selection 
for the following common clinical conditions: 
   
35 Surgical prophylaxis 18 90.0 Retain 
36 Community-acquired pneumonia 16 80.0 Retain 
37 Urinary tract infection 16 80.0 Retain 
38      If YES to any, are these treatment recommendations reviewed annually? 10 50.0 Remove 
39      If YES to any, are these treatment recommendations easily accessible to all  
wards and prescribers (printed ‘pocket guide’ or electronic summaries at 
workstations) 
18 94.7 Retain 
 Protocols    
 Are any of the following actions implemented in your facil ity to improve 
antibiotic prescribing? 
   
40 Automatic changes from intravenous to oral antibiotic therapy in appropriate 
situations? 






41 Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the 
treatment of organisms with reduced susceptibility? 
14 70.0 Retain 
42 Automatic alerts in situations where therapy might be unnecessarily 
duplicative? 
9 43.4 Remove 
43 Time-sensitive automatic stop orders for specified antibiotic prescriptions? 13 65.0 Retain 
No Indicator Retain  % Result 
 Activities and interventions    
44 Do prescribers in your facil ity routinely use antimicrobial ordering forms 
(printed or electronic)? 
13 65.0 Retain 
45 Is it routine practice for specified antimicrobial agents to be approved by a 
physician or pharmacist prior to dispensing (pre-authorization) in your 
facil ity? 
18 90.0 Retain 
46 Is it routine practice for a physician or pharmacist to review incoming 
prescriptions for specified antimicrobial agents (pre-authorization)? 
9 45.0 Remove 
47 Is there dedicated time during which the clinical team reviews antimicrobial 
orders for their assigned patients (antimicrobial ward rounds)? 
13 65.0 Retain 
48 Is there a formal procedure for a physician or pharmacist or other staff 
member to review the appropriateness of an antimicrobial after 48 hours 
from the initial order (post-prescription review)? 
16 80.0 Retain 
49 Are results of antimicrobial audits or reviews provided directly to prescribers 
through in-person, telephone, or electronic communication? 
17 85.0 Retain 
 Monitoring appropriate use    
 Does your facil ity monitor antibiotic use (consumption) at the unit and/or 
facil ity wide level by one of the following metrics: 
   
50 By counts of antibiotic(s) administered to patients per day (Days of Therapy; 
DOT)? 
15 79.0 Retain 
51 By number of grams of antibiotics used (Defined Daily Dose, DDD)? 19 95.0 Retain 
52 By direct expenditure for antibiotics (purchasing costs)? 11 55.0 Remove 
53 Are adverse drug events associated with antimicrobials reported to an 
antimicrobial stewardship team? 









Table 2. Summary Round 1 Results 
 
Results  #  (%) 
Indicators rated in round 1 53  
  Indicators Retained without Revision 26 (49.0%) 
  Indicators Retained and Revised 10 (18.9%) 
  Indicators Removed 17 (32.1%) 
  Indicators Added 8  








Table 3. Round 2 Median Score Results: Rating on Feasibility, Clinical Importance 



































 Governance and Management      
1 Does your facility have a  formally defined 
antimicrobial s tewardship program for ensuring 
appropriate antimicrobial use? 
9 (7.9, 2-9) 8 (8.1, 5-9) 7 (6.8, 5-9) 24 17 
2 Does your facility have a  formal reporting s tructure 
responsible for antimicrobial s tewardship (e.g. a 
multidisciplinary committee focused on appropriate 
antimicrobial use, pharmacy committee, patient 
safety committee or other relevant s tructure)?  
9 (7.8, 4-9) 7 (7.0, 5-8) 7 (5.9, 1-8) 23 16 
3 Does your facility have a  named senior executive 
officer with accountability for antimicrobial 
leadership? 
9 (8.2, 5-9) 6 (6.5, 5-9) 5 (5.1, 1-8) 20 15 
4 Has  an annual report focused on antimicrobial 
s tewardship (summary antimicrobial use and/or 
practices improvement initiatives) been produced 
for your faci lity in the past year? 
9 (8.1, 4-9) 7 (6.5, 5-9) 6 (5.9, 2-8) 22 16 
5 Is  there any budgeted financial support for 
antimicrobial s tewardship activities at your facility 
(e.g., support for salary, tra ining, or IT support)? 
8 (7.4, 1-9) 7 (7.3, 5-9) 5 (5.7, 1-8) 20 15 
 Human Resources      
6 Is  an antimicrobial stewardship team available at 
your faci lity? 
8 (7.7, 4-9) 9 (8.0, 4-9) 7 (6.6, 4-9) 24 17 
7 Is  cl inical infectious disease (ID) consultation 
ava ilable at your facility? 
7 (7.1, 3-9) 8 (7.7, 5-9) 7 (6.5, 5-8) 22 15 
8 Is  there a physician identified as a  leader for 
s tewardship activities at your facility? 
8 (7.9, 4-9) 7 (7.5, 5-9) 7 (6.1, 1-8) 22 15 
9 If YES, Are s tewardship duties included in the job 
description and/or annual review? 
9 (7.9, 5-9) 7 (6.8, 4-9) 5 (4.9, 1-7) 21 16 
10 If YES, Is  this physician trained in infectious 
diseases, clinical microbiology and/or antimicrobial 
s tewardship? 
7 (7.2, 2-9) 8 (7.9, 7-9) 6 (6.1, 1-9) 21 15 
11 Is  there a pharmacist responsible for working to 
improve antimicrobial use at your facility? 
8 (7.8, 4-9) 8 (7.8, 5-9) 6 (5.8, 1-7) 22 16 
12 If YES, has this pharmacist had specialized training 
in infectious disease management or s tewardship? 
7 (6.9, 2-9) 8 (7.6, 5-9) 5 (5.6, 1-8) 20 15 
 Are any of the staff below members involved in 
stewardship activities at your facility? 
     
13 Microbiologist (Laboratory) 8 (7.2, 2-9) 8 (7.3, 5-9) 6 (6.1, 1-9) 22 16 
14 Infection preventionist or hospital epidemiologist 7 (7.1, 2-9) 7 (6.6, 4-9) 6 (6.3, 1-9) 20 14 
15 Information Technology (IT) staff member 6 (6.4, 2-9) 6 (6.3, 4-9) 5 (4.7, 1-6) 17 12 
16 Qual ity improvement s taff member 7 (6.6, 2-9) 6 (5.6, 3-7) 5 (4.3, 1-6) 18 13 
 Laboratory      
17 Does your facility produce a  cumulative 
antimicrobial susceptibility report at least annually? 







































18 If YES, has a  current susceptibility report been 
dis tributed to prescribers at your facility in the last 
year? 
9 (8.1, 5-9) 8 (7.3, 4-9) 7 (6.7, 4-8) 24 17 
 Information Technology      
 Which of the following information technology (IT) 
systems are currently available and used in your 
facility: 
     
19 IT system for prescribing (Computerized Order 
Entry)?  
7 (6.5, 2-9) 7 (6.6, 2-9) 5 (5.3, 2-8) 19 14 
20 If YES, Does the computer order entry system 
support clinical decision making for prescribing 
antimicrobial agents? 
5 (5.4, 2-9) 7 (6.9, 2-9) 6 (5.9, 2-8) 18 12 
21 IT capability to electronically l ink pharmacy, 
laboratory, and medical records? 
6 (6.2, 3-9) 8 (7.5, 5-9) 6 (5.9, 1-9) 20 14 
 Policies for appropriate use      
22 Does your facility have a  defined formulary of 
antimicrobial agents? 
9 (8.7, 7-9) 7 (7.1, 2-9) 6 (6.5, 2-9) 22 16 
23 Does your facility have a  written policy that requires 
prescribers to document in the medical record or 
during order entry a  dose, duration, and indication 
for a l l antimicrobial prescriptions? 
8 (7.2, 4-9) 8 (7.4, 5-9) 6 (5.9, 1-8) 22 16 
 Guidelines      
 Does your facility have facility-specific treatment 
recommendations, based on national guidelines 
and local susceptibility, to assist with antimicrobial 
selection for the following common clinical 
conditions: 
     
24 Surgical prophylaxis 9 (8.4, 6-9) 9 (8.2, 5-9) 7 (6.5, 4-8) 25 18 
25 Community-acquired pneumonia 9 (8.2, 6-9) 8 (7.7, 5-9) 6 (6.3, 5-8) 23 17 
26 Urinary tract infection 9 (8.1, 6-9) 8 (7.9, 5-9) 7 (6.4, 1-9) 24 17 
27 If YES to any of the clinical conditions above, are 
these treatment recommendations easily accessible 
to prescribers on all wards (printed ‘pocket guide’ 
or electronic summaries at workstations) 
9 (8.0, 5-9) 8 (7.8, 5-9) 7 (6.3, 1-9) 23 17 
 Protocols      
 Are any of the following actions implemented in 
your facility to improve antibiotic prescribing? 
     
28 Standardized cri teria for changing from intravenous 
to ora l  antimicrobial therapy in appropriate 
s i tuations? 
8 (7.7, 5-9) 7 (7.0, 4-9) 3 (3.8, 1-9) 18 15 
29 Dose optimization 
(pharmacokinetics/pharmacodynamics) to optimize 
the treatment of organisms with reduced 
susceptibility? 
7 (6.5, 3-9) 8 (7.6, 5-9) 6 (6.3, 3-9) 21 15 
30 Discontinuation of specified antimicrobial 











































 Activities and Interventions      
31 Do prescribers in your facility routinely use 
antimicrobial ordering forms (printed or 
electronic)?  
7 (7.2, 4-9) 6 (5.8, 3-8) 5 (5.1, 1-7) 18 13 
32 Is  i t routine practice for specified antimicrobial 
agents to be approved by a  physician or pharmacist 
prior to dispensing (pre-authorization) in your 
faci lity?  
7 (6.7, 5-9) 8 (7.6, 5-9) 7 (6.5, 5-8) 22 15 
33 Is  there dedicated time during which the clinical 
team reviews antimicrobial orders for their assigned 
patients (antimicrobial ward rounds)?  
6 (5.8, 1-9) 8 (7.5, 3-9) 7 (6.0, 1-8) 21 14 
34 Is  there a formal procedure for a  physician, 
pharmacist, or other s taff member to review the 
appropriateness of an antimicrobial a fter 48 hours 
from the initial order (post-prescription review)?  
7 (6.6, 3-9) 8 (7.9, 5-9) 7 (6.8, 5-8) 22 15 
35 Are results of antimicrobial audits or reviews 
provided directly to prescribers through in-person, 
telephone, or electronic communication?  
7 (6.6, 3-9) 8 (7.8, 6-9) 7 (6.5, 5-8) 22 15 
36 Do prescribers ever receive direct, personalized 
communication about how they can improve their 
antimicrobial prescribing? 
6 (6.1, 3-9) 8 (7.6, 5-9) 7 (6.6, 5-9) 21 14 
 Monitoring appropriate use      
37 Does your facility monitor antimicrobial use by 
counts  of antimicrobial(s) administered to patients 
per day (Days of Therapy; DOT)? 
6 (6.3, 1-9) 7 (6.7, 2-9) 6 (5.9, 1-9) 19 13 
38 Does your facility monitor antimicrobial use by 
number of grams of antimicrobials used (Defined 
Dai ly Dose, DDD)?  
8 (7.9, 4-9) 7 (7.0, 5-9) 6 (6.2, 1-9) 21 15 
39 Does your facility monitor whether the indication 
for treatment is recorded in clinical case notes? 
6 (6.3, 3-9) 7 (7.2, 5-9) 6 (5.8, 1-9) 19 13 
40 If YES, i s  the indication for treatment i s recorded in 
cl inical case notes in >95% of sampled cases in your 
faci lity? 
6 (6.4, 3-9) 8 (7.4, 5-9) 6 (5.8, 1-9) 20 14 
41 Does your facility measure the number of 
antimicrobial prescriptions that are consistent with 
the local treatment recommendations?  
6 (5.7, 3-9) 8 (7.7, 5-9) 6 (6.5, 5-8) 20 14 
42 If YES, are antimicrobial prescriptions compliant 
with facility-specific guideline in >95% of sampled 
cases in your facility? 
6 (5.4, 1-9) 8 (7.6, 1-9) 6 (6.2, 4-8) 20 14 
43 Does your facility measure the duration of surgical 
antimicrobial prophylaxis?  
7 (7.2, 3-9) 8 (7.7, 5-9) 7 (6.7, 5-9) 22 15 
44 If YES, are antimicrobial prescriptions compliant 
with facility-specific guideline in >95% of sampled 
cases in your facility? 








Table 4. Round 2 IPRAS Appropriateness Score: Rating on Feasibility, Clinical 
Importance and Relevance to Minimizing Resistance 
  90/10* 
 






 Governance and management    
1 Does your facility have a  formally defined antimicrobial s tewardship 
program for ensuring appropriate antimicrobial use? 1 4.85 1.35 
2 Does your facility have a  formal reporting s tructure responsible for 
antimicrobial s tewardship (e.g. a multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy committee, patient safety 
committee or other relevant s tructure)? 1.35 3 0.05 
3 Does your facility have a  named senior executive officer with accountability 
for antimicrobial leadership? 4.15 1.35 0.3 
4 Has  an annual report focused on antimicrobial stewardship (summary 
antimicrobial use and/or practices improvement initiatives) been produced 
for your faci lity in the past year? 3.1 1.8 1.85 
5 Is  there any budgeted financial support for antimicrobial s tewardship 
activi ties at your facility (e.g., support for salary, tra ining, or IT support)? -0.75 1.55 0.2 
 Human Resources       
6 Is  an antimicrobial stewardship team available at your facility? 2.75 2.75 1.55 
7 Is  cl inical infectious disease (ID) consultation available at your facility? 1 4.5 1.6 
8 Is  there a physician identified as a  leader for s tewardship activities at your 
faci lity? 4.15 2.75 1.85 
9 If YES, Are s tewardship duties included in the job description and/or annual 
review? 2.75 1.55 -1.95 
10 If YES, Is  this physician trained in infectious diseases, clinical microbiology 
and/or antimicrobial stewardship? 1.35 4.85 1.55 
11 Is  there a pharmacist responsible for working to improve antimicrobial use 
at your facility? 1.35 3.1 1.85 
12 If YES, has this pharmacist had specialized training in infectious disease 
management or s tewardship? 1.35 4.5 1.85 
 Are any of the staff below members involved in stewardship activities at 
your facility?       
13 Microbiologist (Laboratory) 1 1.35 1.55 
14 Infection preventionist or hospital epidemiologist 1.35 1.55 1.55 
15 Information Technology (IT) staff member 1 1.55 2.15 
16 Qual ity improvement s taff member 0.825 1.325 1.35 
 Laboratory       
17 Does your facility produce a  cumulative antimicrobial susceptibility report 
at least annually? 4.85 3.1 1.6 
18 If YES, has a  current susceptibility report been distributed to prescribers at 
your faci lity in the last year? 4.325 1.35 1.6 
 Information Technology       
 Which of the following information technology (IT) systems are currently 
available and used in your facility:       
19 IT system for prescribing (Computerized Order Entry)? 0.65 1.35 1.35 
20 If YES, Does the computer order entry system support cl inical decision 
making for prescribing antimicrobial agents? -0.3 1.55 1.45 
21 IT capability to electronically l ink pharmacy, laboratory, and medical 
records? 1.35 3.3 1.6 















 Guidelines       
 Does your facility have facility-specific treatment recommendations, 
based on national guidelines and local susceptibility, to assist with 
antimicrobial selection for the following common clinical conditions:       
24 Surgical prophylaxis 4.85 4.85 1.6 
25 Community-acquired pneumonia 4.85 4.85 1.85 
26 Urinary tract infection 4.5 4.85 1.6 
27 If YES to any of the clinical conditions above, are these treatment 
recommendations easily accessible to prescribers on all wards (printed 
‘pocket guide’ or electronic summaries at workstations) 3.1 4.85 1.6 
 Protocols       
 Are any of the following actions implemented in your facility to improve 
antibiotic prescribing?       
28 Standardized cri teria for changing from intravenous to oral antimicrobial 
therapy in appropriate s ituations? 2.75 2.75 0.65 
29 Dose optimization (pharmacokinetics/ pharmacodynamics) to optimize the 
treatment of organisms with reduced susceptibility? 1.55 2.75 1.25 
30 Discontinuation of specified antimicrobial prescriptions after a pre-defined 
duration? 1.35 1.35 1.55 
 Activities and interventions       
31 Do prescribers in your facility routinely use antimicrobial ordering forms 
(printed or electronic)? 3.1 0.1 -0.25 
32 Is  i t routine practice for specified antimicrobial agents to be approved by a  
phys ician or pharmacist prior to dispensing (pre-authorization) in your 
faci lity? 3.5 3.1 1.6 
33 Is  there dedicated time during which the clinical team reviews 
antimicrobial orders for their assigned patients (antimicrobial ward 
rounds)? -0.5 4.15 -2.6 
34 Is  there a formal procedure for a  physician, pharmacist, or other s taff 
member to review the appropriateness of an antimicrobial a fter 48 hours 
from the initial order (post-prescription review)? 1 4.15 1.6 
35 Are results of antimicrobial audits or reviews provided directly to 
prescribers through in-person, telephone, or electronic communication? 1.25 4.85 1.8 
36 Do prescribers ever receive direct, personalized communication about how 
they can improve their antimicrobial prescribing? -0.55 4.15 1.8 
 Monitoring appropriate use       
37 Does your facility monitor antimicrobial use by counts of antimicrobial(s) 
administered to patients per day (Days of Therapy; DOT)? 0.85 1.55 0.55 
38 Does your facility monitor antimicrobial use by number of grams of 
antimicrobials used (Defined Daily Dose, DDD)? 4.5 3.35 1.6 
39 Does your facility monitor whether the indication for treatment is recorded 
in cl inical case notes? 1 1.35 1.8 
40 If YES, i s  the indication for treatment i s recorded in cl inical case notes in 
>95% of sampled cases in your facility? 1.35 2.4 0.9 
41 Does your facility measure the number of antimicrobial prescriptions that 
are consistent with the local treatment recommendations? 0.1 4.5 1.6 
42 If YES, are antimicrobial prescriptions compliant with facility-specific 
guideline in >95% of sampled cases in your facility? -3.3 4.85 1.6 
43 Does your facility measure the duration of surgical antimicrobial 
prophylaxis? 1 2.75 1.8 
44 If YES, are antimicrobial prescriptions compliant with facility-specific 













Table 5. Summary Round 2 Results 
 
Results  #  (%) 
Indicators rated in round 2 44  
  Indicators Retained without Revision 26 59.1 
  Indicators Retained and Revised 11 25.0 
  Indicators Removed 6 13.6 
  Indicators Added 1 2.3 























% of Core, Supplemental, 
Remove                                 
C %       S %       X% 
 Governance and management        
1 Does your facility have a  formally defined 
antimicrobial s tewardship program for ensuring 
appropriate antimicrobial use? 
9 (8.5, 5-9) 8 (8.2, 5-9) 17 19 78.9 15.8 5.3 
2 Does your facility have a  formal reporting s tructure 
responsible for antimicrobial s tewardship (e.g. a 
multidisciplinary committee focused on appropriate 
antimicrobial use, pharmacy committee, patient 
safety committee or other relevant s tructure)? 
8 (7.9, 5-9) 7 (7.1, 5-9) 15 18 55.6 38.9 5.6 
3 Does your facility have a  named senior executive 
officer with accountability for antimicrobial 
leadership? 
8 (7.9, 5-9) 6 (6.2, 4-8) 14 19 21.1 68.4 10.5 
4 Has  an annual report focused on antimicrobial 
s tewardship (summary antimicrobial use and/or 
practices improvement initiatives) been produced 
for your faci lity in the past year? 
8 (7.9, 5-9) 7 (6.5, 5-9) 15 19 42.1 52.6 5.3 
5 Does your facility provide any salary support for 
dedicated time for antimicrobial s tewardship 
activi ties? 
7 (7.1, 3-9) 7 (7.4, 5-9) 15 18 42.1 47.4 10.5 
 Human Resources        
6 Is  an antimicrobial stewardship team available at 
your faci lity? 
8 (7.7, 5-9) 9 (8.4, 5-9) 17 18 83.3 11.1 5.6 
7    If YES, Is  an infection preventionist or hospital 
epidemiologist involved in stewardship activities? 7 (7.1, 5-9) 7 (6.8, 3-9) 14 19 0.0 63.2 36.8 
8    If YES, Is  a  microbiologist (laboratory s taff) 
involved in stewardship activities? 8 (7.4, 5-9) 8 (7.1, 5-9) 16 17 11.8 64.7 23.5 
9 Is  cl inical infectious disease (ID) consultation 
ava ilable at your facility? 
7 (6.6, 3-9) 8 (7.8, 5-9) 15 17 29.4 52.9 17.6 
10 there a  physician identified as a leader for 
s tewardship activities at your facility? 8 (8.1, 6-9) 8 (8.1, 7-9) 16 18 88.9 11.1 0.0 
11   If YES, Are s tewardship duties included in the job 
description and/or annual review? 8 (7.4, 3-9) 7 (6.9, 5-9) 15 17 17.6 58.8 23.5 
12   If YES, Is  this physician tra ined in infectious 
diseases, clinical microbiology and/or antimicrobial 
s tewardship? 
7 (7.1, 3-9) 8 (7.7, 5-9) 15 18 16.7 72.2 11.1 
13 Is  there a pharmacist responsible for working to 
improve antimicrobial use at your facility? 8 (7.8, 5-9) 8 (8.0, 5-9) 16 17 76.5 23.5 0.0 
14   If YES, has  this pharmacist had specialized training 
in infectious disease management or s tewardship? 
6 (6.6, 4-9) 7 (7.4, 5-9) 14 17 11.8 76.5 11.8 
 Laboratory        
15 Does your facility produce a  cumulative 
antimicrobial susceptibility report at least annually? 9 (8.2, 5-9) 8 (7.8, 5-9) 17 19 73.7 26.3 0.0 
16    If YES, has a  current susceptibility report been 
dis tributed to prescribers at your facility? 
8 (7.4, 2-9) (7.2, 5-9) 15 18 22.2 50.0 27.8 
 Information Technology        
17 Does your facility have the IT capability to 
electronically link pharmacy records, microbiology 
results, and medical records? 
 


















% of Core, Supplemental, 
Remove 
  (Mean, Range) (Mean, Range)   C % S % X% 
 Policies for appropriate use        
18 Does your facility have a  defined formulary of 
antimicrobial agents? 
9 (8.5, 5-9) 7 (7.3, 5-9) 16 18 44.4 33.3 22.2 
19 Does your facility have a  written policy that requires 
prescribers to document in the medical record or 
during order entry a  dose, duration, and indication 
for a l l antimicrobial prescriptions? 
7 (7.0, 2-9) 8 (7.6, 5-9) 15 18 50.0 38.9 11.1 
 Guidelines        
 Does your facility have facility-specific treatment 
recommendations, based on national guidelines 
and local susceptibility, to assist with antimicrobial 
selection for the following common clinical 
conditions: 
       
20 Surgical prophylaxis 9 (8.6, 7-9) 9 (8.3, 5-9) 18 18 66.7 33.3 0.0 
21 Community-acquired pneumonia 8 (8.3, 7-9) 8 (7.9, 5-9) 16 18 50.0 50.0 0.0 
22 Urinary tract infection 8 (8.3, 6-9) 8 (8.0, 5-9) 16 18 44.4 55.6 0.0 
23    If YES to any of the clinical conditions above, are 
these treatment recommendations easily accessible 
to prescribers on all wards (printed ‘pocket guide’ 
or electronic summaries at workstations) 
8 (7.4, 2-9) 8 (8.1, 5-9) 16 18 22.2 66.7 11.1 
 Protocols        
 Are any of the following actions implemented in 
your facility to improve antibiotic prescribing? 
       
24 Standardized cri teria for changing from intravenous 
to ora l  antimicrobial therapy in appropriate 
s i tuations? 
8 (7.4, 5-9) 7 (7.1, 5-9) 15 18 38.9 38.9 22.2 
25 Dose optimization 
(pharmacokinetics/pharmacodynamics) to optimize 
the treatment of organisms with reduced 
susceptibility? 
7 (6.7, 2-9) 8 (7.5, 3-9) 15 19 26.3 63.2 10.5 
26 Discontinuation of specified antimicrobial 
prescriptions after a pre-defined duration? 
7 (6.7, 5-9) 8 (7.2, 1-9) 15 18 38.9 44.4 16.7 
 Activities and interventions        
27 Is  i t routine practice for specified antimicrobial 
agents to be approved by a  physician or pharmacist 
prior to dispensing (pre-authorization) in your 
faci lity? 
7 (6.9, 5-9) 8 (7.9, 5-9) 15 18 38.9 55.6 5.6 
28 Is  there a formal procedure for a  physician, 
pharmacist, or other s taff member to review the 
appropriateness of an antimicrobial a fter 48 hours 
from the initial order (post-prescription review)? 
7 (6.6, 3-9) 8 (8.1, 5-9) 15 18 72.2 27.8 0.0 
29 Are results of antimicrobial audits or reviews 
provided directly to prescribers through in-person, 
telephone, written or electronic communication?  
7 (6.7, 3-9) 8 (8.1, 7-9) 15 19 57.9 31.6 10.5 
30 Do prescribers receive education about how they 
can improve their antimicrobial prescribing? 7 (7.2, 3-9) 8 (7.7, 4-9) 15 17 64.7 29.4 5.9 
 Monitoring appropriate use        
31 Does your facility monitor antimicrobial use by 
grams [Defined Daily Dose (DDD)] or counts [Days of 
Therapy (DOT)] of antimicrobial(s) by patients per 
day? 


















% of Core, Supplemental, 
Remove 
 (Mean, Range) (Mean, Range) C % S % X% 
32 Does your facility monitor whether the indication 
for treatment is captured in the medical record? 
6 (6.3, 4-9) 7 (7.2, 5-9) 13 18 27.8 61.1 11.1 
33    If YES, i s  the indication for treatment i s captured 
in the medical record in >80% of sampled cases in 
your faci lity? 
6 (5.9, 1-8) 8 (7.4, 5-9) 14 17 5.9 70.6 23.5 
34 Does your facility measure the number of 
antimicrobial prescriptions that are consistent with 
the local treatment recommendations for either UTI 
or CAP? 
6 (6.3, 4-9) 8 (7.7, 5-9) 14 18 38.9 50.0 11.1 
35    If YES, are antimicrobial prescriptions for UTI 
compl iant with facility-specific guideline in >80% of 
sampled cases in your facility? 
7 (6.3, 3-8) 8 (7.7, 5-9) 15 17 0.0 76.5 23.5 
36    If YES, are antimicrobial prescriptions for CAP 
compl iant with facility-specific guideline in >80% of 
sampled cases in your facility? 
6 (6.2, 3-9) 8 (7.6, 59) 15 17 5.9 70.6 23.5 
37 Does your facility review surgical antimicrobial 
prophylaxis? 
7 (7.3, 3-9) 8 (7.9, 5-9) 15 18 50.0 50.0 0.0 
38 If YES, are antimicrobial prescriptions compliant 
with facility-specific guidelines in >80% of sampled 
cases in your facility? 
7 (7.1, 3-9) 8 (7.8, 5-9) 15 17 29.4 52.9 17.6 













90/10 * IPRAS-IPR (+=agreement) 
 
Feasibility Clinical Importance 
 Governance and management   
1 Does your facil ity have a formally defined antimicrobial stewardship 
program for ensuring appropriate antimicrobial use? 
5.9 6.2 
2 
Does your facil ity have a formal reporting structure responsible for 
antimicrobial stewardship (e.g. a multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy committee, patient safety 
committee or other relevant structure)? 
2.7 1.5 
3 Does your facil ity have a named senior executive officer with accountability 
for antimicrobial leadership? 
4.8 1.6 
4 
Has an annual report focused on antimicrobial stewardship (summary 
antimicrobial use and/or practices improvement initiatives) been produced 
for your facil ity in the past year? 
4.8 1.8 
5 Does your facil ity provide any salary support for dedicated time for 
antimicrobial stewardship activities? 
2.0 2.7 
 Human Resources   
6 Is an antimicrobial stewardship team available at your facil ity? 3.1 6.6 
7    If YES, Is an infection preventionist or hospital epidemiologist involved in 
stewardship activities? 
2.7 1.6 
8    If YES, Is a microbiologist (laboratory staff) involved in stewardship activities? 2.6 1.3 
9 Is cl inical infectious disease (ID) consultation available at your facil ity? 1.0 1.3 
10 Is there a physician identified as a leader for stewardship activities at your facil ity? 4.8 4.8 
11   If YES, Are stewardship duties included in the job description and/or annual review? 2.6 1.3 
12   If YES, Is this physician trained in infectious diseases, cl inical microbiology 
and/or antimicrobial stewardship? 
3.3 3.1 
13 Is there a pharmacist responsible for working to improve antimicrobial use at your facil ity? 2.6 4.8 
14   If YES, has this pharmacist had specialized training in infectious disease 











90/10 * IPRAS-IPR (+=agreement) 
Feasibility Clinical Importance 
 Laboratory   
15 Does your facil ity produce a cumulative antimicrobial susceptibility report at 
least annually? 
4.8 4.5 
16    If YES, has a current susceptibility report been distributed to prescribers at your facil ity? 1.3 2.9 
 Information Technology   
17 Does your facil ity have the IT capability to electronically l ink pharmacy 
records, microbiology results, and medical records? 
1.4 4.8 
 Policies for appropriate use   
18 Does your facil ity have a defined formulary of antimicrobial agents? 6.2 2.7 
19 
Does your facil ity have a written policy that requires prescribers to 
document in the medical record or during order entry a dose, duration, and 
indication for all antimicrobial prescriptions? 
1.3 4.8 
 Guidelines   
 Does your facility have facility-specific treatment recommendations, based 
on national guidelines and local susceptibility, to assist with antimicrobial 
selection for the following common clinical conditions: 
  
20 Surgical prophylaxis 6.2 4.8 
21 Community-acquired pneumonia 4.8 4.8 
22 Urinary tract infection 4.8 4.8 
23    If YES to any of the clinical conditions above, are these treatment 
recommendations easily accessible to prescribers on all  wards (printed 
‘pocket guide’ or electronic summaries at workstations) 
2.6 4.8 
 Protocols   
 Are any of the following actions implemented in your facility to improve 
antibiotic prescribing? 
  
24 Standardized criteria for changing from intravenous to oral antimicrobial 
therapy in appropriate situations? 
4.1 1.5 
25 Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the 
treatment of organisms with reduced susceptibility? 
1.5 4.3 













90/10 * IPRAS-IPR 
(+=agreement) 
 Feasibility Clinical Importance 
 Activities and interventions   
27 
Is it routine practice for specified antimicrobial agents to be approved by a 




Is there a formal procedure for a physician, pharmacist, or other staff 
member to review the appropriateness of an antimicrobial after 48 hours 
from the initial order (post-prescription review)? 
3.0 4.8 
29 Are results of antimicrobial audits or reviews provided directly to prescribers 
through in-person, telephone, written or electronic communication?  
1.8 4.8 
30 Do prescribers receive education about how they can improve their antimicrobial prescribing? 1.3 3.8 
 Monitoring appropriate use   
31 
Does your facil ity monitor antimicrobial use by grams [Defined Daily Dose 




Does your facil ity monitor whether the indication for treatment is captured 
in the medical record? 1.5 1.3 
33    If YES, is the indication for treatment is captured in the medical record in 
>80% of sampled cases in your facil ity? 
1.1 2.6 
34 
Does your facil ity measure the number of antimicrobial prescriptions that 




   If YES, are antimicrobial prescriptions for UTI compliant with facil ity-
specific guideline in >80% of sampled cases in your facil ity? 1.1 2.6 
36    If YES, are antimicrobial prescriptions for CAP compliant with facil ity-
specific guideline in >80% of sampled cases in your facil ity? 
-0.2 2.6 
37 Does your facil ity review surgical antimicrobial prophylaxis? 2.7 4.1 
38 If YES, are antimicrobial prescriptions compliant with facility-specific 
guidelines in >80% of sampled cases in your facil ity? 
0.8 2.6 





Table 8. Indicator changes from Round 1 to Round 3 
ROUND 1 ROUND 2 ROUND 3 FINAL SET 
Governance and management   Strict criteria* Liberal criteria** 
1. Does your facil ity have a formal 
mandate for ensuring appropriate 
antimicrobial use (antimicrobial 
stewardship)? 
1. Does your facil ity have a formally 
defined antimicrobial stewardship 
program for ensuring appropriate 
antimicrobial use? 
1. Does your facil ity have a formally 
defined antimicrobial stewardship 
program for ensuring appropriate 
antimicrobial use? 
Core Core 
2. Does your facil ity have a 
multidisciplinary committee focused on 
appropriate antimicrobial use? (e.g., 
antimicrobials stewardship team)  
2. Does your facil ity have a formal 
reporting structure responsible for 
antimicrobial stewardship (e.g. a 
multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy 
committee, patient safety committee or 
other relevant structure)?  
2. Does your facil ity have a formal 
reporting structure responsible for 
antimicrobial stewardship (e.g. a 
multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy 
committee, patient safety committee or 
other relevant structure)?  
Supplemental Core 
3. If YES, Does this stewardship team meet 
regularly (at least twice a year)? 
    
 3. Does your facil ity have a named senior 
executive officer with accountabil ity for 
antimicrobial leadership? 
3. Does your facil ity have a named senior 
executive officer with accountabil ity for 
antimicrobial leadership? 
Supplemental Supplemental 
4. If YES, Are minutes from the 
stewardship team meetings sent to 
executive leadership? 
    
5. Has an annual report focused on 
antimicrobial stewardship (summary 
antimicrobial use and/or practices 
improvement initiatives) been produced 
for your facil ity in the past year? 
4. Has an annual report focused on 
antimicrobial stewardship (summary 
antimicrobial use and/or practices 
improvement initiatives) been produced 
for your facil ity in the past year? 
4. Has an annual report focused on 
antimicrobial stewardship (summary 
antimicrobial use and/or practices 
improvement initiatives) been produced 
for your facil ity in the past year? 
Supplemental Supplemental 
6. Does your facil ity receive any budgeted 
financial support for antibiotic stewardship 
activities (e.g., support for salary, training, 
or IT support)? 
5. Is there any budgeted financial support 
for antimicrobial stewardship activities at 
your facil ity (e.g., support for salary, 
training, or IT support)? 
5. Does your facil ity provide any salary 
support for dedicated time for 
antimicrobial stewardship activities? 
Supplemental Supplemental 
Human Resources     
 6. Is an antimicrobial stewardship team 
available at your facil ity? 
6. Is an antimicrobial stewardship team 
available at your facil ity? 
Core Core 
7. Is cl inical infectious disease (ID) 
consultation available at your facil ity? 
7. Is cl inical infectious disease (ID) 
consultation available at your facil ity? 
9. Is cl inical infectious disease (ID) 
consultation available at your facil ity? 
Supplemental Supplemental 
8. Is a full-time pharmacist available on site 
at your facil ity? 
    
9. Does your facil ity perform the majority 
of its microbiology testing on site? 






ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
10. Is there a physician identified as a 
leader for stewardship activities at your 
facil ity? 
8. Is there a physician identified as a leader 
for stewardship activities at your facil ity? 
10. Is there a physician identified as a 
leader for stewardship activities at your 
facil ity  
Core Core  
 9. If YES, Are stewardship duties included 
in the job description and/or annual 
review? 
11. If YES, Are stewardship duties included 
in the job description and/or annual 
review? 
Remove Supplemental 
11. If YES, does this physician receive any 
direct salary support for this role? 
[Governance and management] 5. Is there 
any budgeted financial support for 
antimicrobial stewardship activities at your 
facil ity (e.g., support for salary, training, or 
IT support)? 
[Governance and management] 5. Does 
your facil ity provide any salary support for 










12. If YES, Is this physician trained in 
infectious diseases? 
10. If YES, Is this physician trained in 
infectious diseases, cl inical microbiology 
and/or antimicrobial stewardship? 
12. If YES, Is this physician trained in 
infectious diseases, cl inical microbiology 
and/or antimicrobial stewardship? 
Supplemental Supplemental 
13. Is there a pharmacist leader 
responsible for working to improve 
antibiotic use at your facil ity?  
11. Is there a pharmacist responsible for 
working to improve antimicrobial use at 
your facil ity? 
13. Is there a pharmacist responsible for 
working to improve antimicrobial use at 
your facil ity? 
Core Core 
14. If YES, are stewardship duties included 
in the job description and/or annual 
review?  
    
15. If YES, has the lead pharmacist had 
specialized training in infectious disease 
management or stewardship? 
12. If YES, has this pharmacist had 
specialized training in infectious disease 
management or stewardship? 
14. If YES, has this pharmacist had 
specialized training in infectious disease 
management or stewardship? 
Supplemental Supplemental 
Are any of the staff below members of the 
stewardship team at your facil ity? 
Are any of the staff below members 
involved in stewardship activities at your 
facil ity? 
   
16. Microbiologist (Laboratory)  13. Microbiologist (Laboratory)  8. If YES, Is a microbiologist (laboratory 
staff) involved in stewardship activities? 
Remove Supplemental 
17. Infection preventionist 14. Infection preventionist or hospital 
epidemiologist 
7. If YES, Is an infection preventionist or 
hospital epidemiologist involved in 
stewardship activities? 
Remove Supplemental 
18. Hospital epidemiologist     
19. Information Technology (IT) staff 
member 
15. Information Technology (IT) staff 
member 
   
 16. Quality improvement staff member 
 






ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
Laboratory     
20. Does your facil ity produce an 
antibiogram (cumulative antimicrobial 
susceptibility report) at least annually? 
17. Does your facil ity produce a cumulative 
antimicrobial susceptibility report at least 
annually? 
15. Does your facil ity produce a cumulative 
antimicrobial susceptibility report at least 
annually? 
Core Core 
21. Is antimicrobial selection for the 
guidelines informed by the current 
antibiogram? 
    
 18. If YES, has a current susceptibility 
report been distributed to prescribers at 
your facil ity in the last year? 
16. If YES, has a current susceptibility 
report been distributed to prescribers at 
your facil ity? 
Remove Supplemental 
Information Technology     
Which of the following information 
technology (IT) systems are currently 
available and used in your facil ity: 
Which of the following information 
technology (IT) systems are currently 
available and used in your facil ity: 
   
22. Electronic medical or health record?     
23. IT system for prescribing 
(Computerized Order Entry)? 
19. IT system for prescribing 
(Computerized Order Entry)? 
   
24. IT system for medication dispensing or 
administration? 
    
25. IT capability to electronically l ink 
pharmacy, laboratory, and medical 
records? 
21. IT capability to electronically l ink 
pharmacy, laboratory, and medical 
records? 
17. Does your facil ity have the IT capability 
to electronically l ink pharmacy records, 
microbiology results, and medical records? 
Supplemental Supplemental 
26. Does the computer order entry system 
support clinical decision making for 
prescribing antimicrobial agents? 
20. If YES, Does the computer order entry 
system support clinical decision making for 
prescribing antimicrobial agents? 
   
Education     
27. Has your facil ity given an educational 
presentation on improving antibiotic 
prescribing within the last year?   
    
28. Do prescribers ever receive direct, 
personalized communication about how 




[Activities and intervention] 36.Do 
prescribers ever receive direct, 
personalized communication about how 
they can improve their antimicrobial 
prescribing? 
[Activities and interventions] 30. Do 
prescribers receive education about how 













ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
29. Has a current antibiogram been 
distributed to prescribers at your facil ity in 
the last year? 
[Laboratory] 18. If YES, has a current 
susceptibility report been distributed to 
prescribers at your facil ity in the last year? 
[Laboratory] 16. If YES, has a current 
susceptibility report been distributed to 





30. Does your facil ity have a training 
strategy to promote appropriate 
antimicrobial use? 
    
31. Are patients or their legal guardian 
routinely given information about 
antimicrobials they have received 
(indication, course length, possible risks, 
what to do if side effects develop at home 
etc.)? 
    
Policies for appropriate use     
32. Does your facil ity have a defined 
formulary of antimicrobial agents? 
22. Does your facil ity have a defined 
formulary of antimicrobial agents? 
18. Does your facil ity have a defined 
formulary of antimicrobial agents? 
Remove Remove 
33. Is there a written policy for approval of 
new antimicrobial agents onto the 
formulary? 
    
34. Does your facil ity have a written policy 
that requires prescribers to document in 
the medical record or during order entry a 
dose, duration, and indication for all  
antibiotic prescriptions? 
23. Does your facil ity have a written policy 
that requires prescribers to document in 
the medical record or during order entry a 
dose, duration, and indication for all  
antimicrobial prescriptions? 
19. Does your facil ity have a written policy 
that requires prescribers to document in 
the medical record or during order entry a 
dose, duration, and indication for all  
antimicrobial prescriptions? 
Supplemental Core 
Guidelines     
Does your facil ity have facil ity-specific 
treatment recommendations, based on 
national guidelines and local susceptibility, 
to assist with antibiotic selection for the 
following common clinical conditions: 
Does your facil ity have facil ity-specific 
treatment recommendations, based on 
national guidelines and local susceptibility, 
to assist with antimicrobial selection for 
the following common clinical conditions: 
Does your facil ity have facil ity-specific 
treatment recommendations, based on 
national guidelines and local susceptibility, 
to assist with antimicrobial selection for 
the following common clinical conditions: 
  
35. Surgical prophylaxis 24. Surgical prophylaxis 20. Surgical prophylaxis Supplemental Core 
36. Community-acquired pneumonia 25. Community-acquired pneumonia 21. Community-acquired pneumonia Supplemental Core 
37. Urinary tract infection 26. Urinary tract infection 22. Urinary tract infection Supplemental Supplemental 
38.    If YES to any, are these treatment 
recommendations reviewed annually? 
 
 






ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
39.   If YES to any, are these treatment 
recommendations easily accessible to all  
wards and prescribers (printed ‘pocket 
guide’ or electronic summaries at 
workstations) 
27. If YES to any of the clinical conditions 
above, are these treatment 
recommendations easily accessible to 
prescribers on all  wards (printed ‘pocket 
guide’ or electronic summaries at 
workstations) 
23. If YES to any of the clinical conditions 
above, are these treatment 
recommendations easily accessible to 
prescribers on all  wards (printed ‘pocket 
guide’ or electronic summaries at 
workstations) 
Supplemental Supplemental 
Protocols     
Are any of the following actions 
implemented in your facil ity to improve 
antibiotic prescribing? 
Are any of the following actions 
implemented in your facil ity to improve 
antibiotic prescribing? 
Are any of the following actions 
implemented in your facil ity to improve 
antibiotic prescribing? 
  
40. Automatic changes from intravenous 
to oral antibiotic therapy in appropriate 
situations? 
28. Standardized criteria for changing from 
intravenous to oral antimicrobial therapy 
in appropriate situations? 
24. Standardized criteria for changing from 
intravenous to oral antimicrobial therapy 
in appropriate situations? 
Remove Remove 
41. Dose optimization 
(pharmacokinetics/pharmacodynamics) to 
optimize the treatment of organisms with 
reduced susceptibility? 
29. Dose optimization 
(pharmacokinetics/pharmacodynamics) to 
optimize the treatment of organisms with 
reduced susceptibility? 
25. Dose optimization 
(pharmacokinetics/pharmacodynamics) to 
optimize the treatment of organisms with 
reduced susceptibility? 
Supplemental Supplemental 
42. Automatic alerts in situations where 
therapy might be unnecessarily 
duplicative? 
    
43. Time-sensitive automatic stop orders 
for specified antibiotic prescriptions? 
30. Discontinuation of specified 
antimicrobial prescriptions after a pre-
defined duration? 
26. Discontinuation of specified 
antimicrobial prescriptions after a pre-
defined duration? 
Remove Remove 
Activities and interventions     
44. Do prescribers in your facil ity routinely 
use antimicrobial ordering forms (printed 
or electronic)? 
31. Do prescribers in your facil ity routinely 
use antimicrobial ordering forms (printed 
or electronic)? 
   
45. Is it routine practice for specified 
antimicrobial agents to be approved by a 
physician or pharmacist prior to dispensing 
(pre-authorization) in your facil ity? 
32. Is it routine practice for specified 
antimicrobial agents to be approved by a 
physician or pharmacist prior to dispensing 
(pre-authorization) in your facil ity? 
27. Is it routine practice for specified 
antimicrobial agents to be approved by a 
physician or pharmacist prior to dispensing 
(pre-authorization) in your facil ity? 
Supplemental Supplemental 
46. Is it routine practice for a physician or 
pharmacist to review incoming 
prescriptions for specified antimicrobial 
agents (pre-authorization)? 
 







ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
47. Is there dedicated time during which 
the clinical team reviews antimicrobial 
orders for their assigned patients 
(antimicrobial ward rounds)? 
33. Is there dedicated time during which 
the clinical team reviews antimicrobial 
orders for their assigned patients 
(antimicrobial ward rounds)? 
   
48. Is there a formal procedure for a 
physician or pharmacist or other staff 
member to review the appropriateness of 
an antimicrobial after 48 hours from the 
initial order (post-prescription review)? 
34. Is there a formal procedure for a 
physician, pharmacist, or other staff 
member to review the appropriateness of 
an antimicrobial after 48 hours from the 
initial order (post-prescription review)? 
28. Is there a formal procedure for a 
physician, pharmacist, or other staff 
member to review the appropriateness of 
an antimicrobial after 48 hours from the 
initial order (post-prescription review)? 
Core Core 
49. Are results of antimicrobial audits or 
reviews provided directly to prescribers 
through in-person, telephone, or 
electronic communication? 
35. Are results of antimicrobial audits or 
reviews provided directly to prescribers 
through in-person, telephone, or 
electronic communication? 
29. Are results of antimicrobial audits or 
reviews provided directly to prescribers 
through in-person, telephone, written or 
electronic communication?  
Supplemental Core 
 36. Do prescribers ever receive direct, 
personalized communication about how 
they can improve their antimicrobial 
prescribing? 
30. Do prescribers receive education about 
how they can improve their antimicrobial 
prescribing? 
Supplemental Core 
Monitoring appropriate use     
Does your facil ity monitor antibiotic use 
(consumption) at the unit and/or facil ity 
wide level by one of the following metrics: 
    
50. By counts of antibiotic(s) administered 
to patients per day (Days of Therapy; 
DOT)? 
37. Does your facil ity monitor 
antimicrobial use by counts of 
antimicrobial(s) administered to patients 
per day (Days of Therapy; DOT)? 
31. Does your facil ity monitor 
antimicrobial use by grams [Defined Daily 
Dose (DDD)] or counts [Days of Therapy 





51. By number of grams of antibiotics used 
(Defined Daily Dose, DDD)? 
38. Does your facil ity monitor 
antimicrobial use by number of grams of 
antimicrobials used (Defined Daily Dose, 
DDD)? 
[37 and 38 merged above]31. Does your 
facil ity monitor antimicrobial use by grams 
[Defined Daily Dose (DDD)] or counts [Days 
of Therapy (DOT)] of antimicrobial(s) by 





52. By direct expenditure for antibiotics 
(purchasing costs)? 








ROUND 1 ROUND 2 ROUND 3 FINAL SET 
   Strict criteria* Liberal criteria** 
53. Are adverse drug events associated 
with antimicrobials reported to an 
antimicrobial stewardship team? 
    
 39. Does your facil ity monitor whether the 
indication for treatment is recorded in 
clinical case notes? 
32. Does your facil ity monitor whether the 
indication for treatment is captured in the 
medical record? 
Supplemental Supplemental 
 40. If YES, is the indication for treatment is 
recorded in clinical case notes in >95% of 
sampled cases in your facil ity? 
33. If YES, is the indication for treatment is 
captured in the medical record in >80% of 
sampled cases in your facil ity? 
Remove Supplemental 
 41. Does your facil ity measure the number 
of antimicrobial prescriptions that are 
consistent with the local treatment 
recommendations? 
34. Does your facil ity measure the number 
of antimicrobial prescriptions that are 
consistent with the local treatment 
recommendations for either UTI or CAP? 
Supplemental Supplemental 
 42. If YES, are antimicrobial prescriptions 
compliant with facil ity-specific guideline in 
>95% of sampled cases in your facil ity? 
35. If YES, are antimicrobial prescriptions 
for UTI compliant with facil ity-specific 
guideline in >80% of sampled cases in your 
facil ity? 
Remove Supplemental 
  36. If YES, are antimicrobial prescriptions 
for CAP compliant with facil ity-specific 
guideline in >80% of sampled cases in your 
facil ity? 
Remove Supplemental 
 43. Does your facil ity measure the duration 
of surgical antimicrobial prophylaxis? 
37. Does your facil ity review surgical 
antimicrobial prophylaxis? 
Supplemental Core 
 44. If YES, are antimicrobial prescriptions 
compliant with facil ity-specific guideline in 
>95% of sampled cases in your facil ity? 
38. If YES, are antimicrobial prescriptions 
compliant with facil ity-specific guidelines 
in >80% of sampled cases in your facil ity? 
Supplemental Supplemental 
 
*Strict criteria: If the remove "X" percentage was ≥ 20.0%, then the indicator was removed. If core “C” percentage was ≥ to 70.0%, then that indicator was retained 
as a Core Indicator. The remaining indicators were retained as a Supplemental Indicator.  
**Liberal criteria: If the remove "x" percentage was ≥ 20.0%, then the indicator was removed, unless the supplemental "S" percentage was >=50% for the same 
indicator, then that indicator was retained as supplemental. If the core “C” percentage was ≥ 50.0%, then that indicator was kept as a Core Indicator. The 













D. Comparison of TATFAR antimicrobial stewardship indicators to other previously developed assessments 
Table 9. TATFAR indicators compared to ASP assessments in EU member states 
TATFAR Core Indicators:  
17 core structure and process indicators 
for hospital antimicrobial stewardship 
programs 
Antibiotic Strategy International (ABI) 
 
58 indicators developed,  
10 identified as ‘minimal set of key 
indicators’ (bolded) 
Annual French hospital survey  
CCLIN Sud-Ouest 
 
24 questions,  
13 questions included in the national 
mandatory composite indicator on 
prudent use of antibiotics 
mandatory(bolded)  
UK Antimicrobial Stewardship 
Assessment Tool (ASAT) 
 
82 questions, embedded scoring 
No prioritization of questions 
Does your facility have a formal 
antimicrobial stewardship program 
accountable for ensuring appropriate 
antimicrobial use?  
*Formal mandate for hospital multi-
disciplinary antibiotic management 
team (AMT) existing 
 
Formal mandate for AB officer existing 
 
Does the Trust have a written strategy 
for ensuring the quality of 
antimicrobial use? 
Is antimicrobial stewardship addressed 
within the Trust Infection Control 
Strategy? 
Does the DIPC have antimicrobial 
stewardship included within their job 
description? 
Does the Trust have an antimicrobial 
committee or equivalent accountable to 
the IC/DT Committee?* How often 
does it meet? Does it have minutes or 
an action list? 
Does your facility have a formal 
organizational structure responsible for 
antimicrobial stewardship (e.g., a 
multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy 
committee, patient safety committee or 
other relevant structure)?  
*AB officer or AMT member is 
member of the drugs and therapeutics 
committee 
 
AMT (multi-disciplinary antibiotic 
management team) meetings performed at 
least bi-monthly 
 
AB policy and progress report 
disseminated to medical director 
by AMT/AB officer (also to infection 
control committee and drugs and 
therapeutics committee) 
Does your hospital have a local 
multidisciplinary antibiotic committee? 
 
If yes, number of meetings held last year: 
 
Is an antimicrobial stewardship team 
available at your facility (e.g., greater 
than one staff member supporting 
clinical decisions to ensure appropriate 
antimicrobial use)?  
*Bedside expert consultant advice 
regarding antibiotics by 
microbiologist/infectious disease 
specialist/antibiotic officer on request 
available on the same day 
 
*Regular ward rounds by members of 
the AMT (multi-disciplinary antibiotic 
management team) performed (at least 
weekly) 









Is there a physician identified as a leader 
for antimicrobial stewardship activities 
at your facility?  
 
Does your hospital have one or several 
antibiotic advisors?  
If yes, specify their specialty 
If yes, specify their diploma  
If yes, time spent by the antibiotic advisor 
in no. days / week: 
What time is dedicated by the pharmacist 
to antibiotic dispensation (in no. hours 
per week)? 
 
Is there a pharmacist responsible for 
ensuring antimicrobial use at your 
facility? 
 
Is there a substantive AM pharmacist 
post in place? 
Does your facility provide any salary 
support for dedicated time for 
antimicrobial stewardship activities (e.g., 
percentage of full-time equivalent (FTE) 
for ensuring appropriate antimicrobial 
use)? 
Time resources for AMT defined  
Time resources for AB officer defined 
What WTE AM Pharmacy staff/500 
beds is spent on antimicrobial duties? 
 
Does your facility have the IT capability 
to support the needs of the antimicrobial 
stewardship activities? 
Computerised antibiotic 
prescription/order form/system available 
Does your hospital have information 
technology support for prescribing 
antibiotics? 
 
Does your hospital have information 
technology support for pharmaceutical 
analysis of antibiotic prescriptions? 
 
Does your hospital have computerized 
link between pharmacy, laboratory 
and clinical wards? 
 
Does your facility have facility-specific 
treatment recommendations based on 
local antimicrobial susceptibility to assist 
with antimicrobial selection for common 
clinical conditions? 
Local clinical practice guidelines/ guide 
for microbiologically 
documented therapy available  
[As above] updated biannually 
 
*Local clinical practice guidelines/guide 
for empirical therapy available 
[As above] updated biannually 
 
*Local clinical practice guidelines/guide 
for surgical antibiotic prophylaxis 
available 
Are there local guidelines for antibiotic 
surgical prophylaxis, endorsed by the 
antibiotic committee, based on 
nationally agreed guidelines? 
 
Are there local guidelines for first line 
antibiotic treatment for main 
infections, endorsed by the antibiotic 
committee? 
Are peer-reviewed, evidence-based, 
guidelines available for treatment of 
common infections?** 
Are peer-reviewed, evidence-based, 
surgical prophylaxis guidelines 
available for the common procedures? 
Is selection for the guidelines informed 







Do AM guidelines provide guidance on 
typical duration of treatment for each 
indication? 
Do AM guidelines provide guidance on 
choice, dose, route, IV switch for each 
indication as appropriate? 
Does your facility have a written policy 
that requires prescribers to document in 
the medical record or during order entry 
a dose, duration, and indication for all 
antimicrobial prescriptions? 
  Does the AM policy stipulate that 
indication should be recorded before 
AMs are prescribed? 
Does the AM Policy stipulate that 
course length or review date is 
recorded on the prescription chart at 
time of prescribing? 
Is it routine practice for specified 
antimicrobial agents to be approved by a 
physician or pharmacist in your facility 
(e.g., pre-authorization)? 
Special request/order form for (selected) 
antimicrobial drugs available 
Are there specific requirements for the 
dispensation of some antibiotics? 
(restricted antibiotics / controlled 
dispensation) 
 
If yes, are restricted antibiotics 
dispensed for a limited duration 
allowing assessment after 2-3 days 
(prescriptions with stop-order)? 
 
If yes, are restricted antibiotics 
dispensed only if clinical information 
is provided? 
 
If yes, are restricted antibiotics 
dispensed only if microbiologic 
information is provided? 
 
If yes, are restricted antibiotics 
dispensed if prior approval by the 
antibiotic advisor? 
Is there a system for restricted access to 
certain Formulary antimicrobials within 
the trust? 







Is there a formal procedure for a 
physician, pharmacist, or other staff 
member to review the appropriateness of 
an antimicrobial after 48 hours from the 
initial order (post-prescription review)? 
Clinical audit by AB officer for evaluation 
of prescribers’ Time-limited drug 
delivery/automatic stop order available 
compliance with streamlining drugs on 
days 2–3 
 Does the AM Policy stipulate that 
appropriate de-escalation of therapy 
takes place? 
Has your facility produced a cumulative 
antimicrobial susceptibility report in the 
past year? 
Antibiotic resistance data regarding 
MRSA analysed and written report 
provided at least 1×/year 
[As above] regarding ESBL 
[As above] other than MRSA and 
ESBL 
Does your hospital monitor antimicrobial 
resistance? 
 
Does your facility monitor if the 
indication is captured in the medical 
record for all antimicrobial 
prescriptions? 
  Is there an AM audit strategy/program? 
Is compliance with AM Prescribing 
Policy audited and fed back in each 
specialty at least once a year? 
Does your facility audit or review 
surgical antimicrobial prophylaxis choice 
and duration? 
  Is adherence to pertinent surgical 
prophylaxis guidelines audited and fed 
back in each specialty at least once a 
year? 
Are results of antimicrobial audits or 
reviews communicated directly with 
prescribers?  
*Clinical audit of prescribers’ 
compliance with local clinical 
guidelines/guide performed by 
AMT/AB officer 
 
*Prescriber education by personalised 
interactive methods (like daily ward 
rounds) performed 
 
ABS-related formal exchange of 
experiences (e.g. meeting) of 
AMT with general practitioners min. 
1×/year performed 
 
AB consumption feedback to the ward at 
least 1×/year 
Did your hospital carried out 
prescribing practice audit last year?  
If yes, did you perform feedback to 
prescribers? 
Are incident reports of AM usage fed 







Does your facility monitor antimicrobial 
use by grams [Defined Daily Dose 
(DDD)] or counts [Days of Therapy 
(DOT)] of antimicrobial(s) by patients 
per days? 
Drug use Total annual antibacterial (ATC 
J01) consumption for monitoring local 
temporal trend 
 
Annual analysis of AB consumption data 
(in DDD or RDD) 
-by drug class 
-available on department level (i.e. by 
discipline) 
-available on ward level 
Does your hospital monitor antibiotic 
consumption expressed in number of 
Defined Daily Doses (DDD) per 1000 
patient-days? 
Is antimicrobial consumption 
monitored eg DDDs per activity? 
Is antimicrobial consumption reported 
to clinical specialties? 
Has an annual report focused on 
antimicrobial stewardship (summary 
antimicrobial use and/or practices 
improvement initiatives) been produced 
for your facility in the past year? 
AB policy plan with quantitative 
objectives for performance indicators 
published annually by AMT/AB officer 
Prospective drug use evaluation on the 
wards by AB officer at least 1 
drug/annually 
Did your hospital carried out 
prescribing practice audit last year?  
 
If yes, were results discussed during 
an antibiotic committee?  
 
Does the Trust board including non-
Exec directors receive an annual report 
pertaining to AM stewardship? 
Are incident reports of AM usage fed 





TATFAR Supplemental Indicators: structure and 
process indicators for hospital antimicrobial 
stewardship programs 
Antibiotic Strategy International 
(ABI) 
 
58 indicators developed,  
10 identified as ‘minimal set 
of key indicators’ (bolded) 
Annual French hospital survey  
CCLIN Sud-Ouest 
 
24 questions,  
13 questions included in the national 
mandatory composite indicator on 
prudent use of antibiotics 
mandatory(bolded)  
UK Antimicrobial Stewardship 
Assessment Tool (ASAT) 
 
82 questions, embedded scoring 
No prioritization of questions 
Does your facility have a named senior executive 
officer with accountability for antimicrobial 
leadership? 
   
Is an antimicrobial stewardship team available at 
your facility (e.g., greater than one staff member 










If YES, Is an infection preventionist or 
hospital epidemiologist involved in 
stewardship activities? 
If YES, Is a microbiologist (laboratory 
staff) involved in stewardship activities? 
   
Is clinical infectious disease (ID) consultation 
available at your facility? 
  Is advice from a medical 
microbiologist/ID physician available 
by telephone? 
Is there a physician identified as a leader for 
antimicrobial stewardship activities at your facility?  
If YES, Are stewardship duties included 
in the job description and/or annual 
review? 
   
If YES, Is this physician trained in 
infectious diseases, clinical microbiology 
and/or antimicrobial stewardship? 
   
Is there a pharmacist responsible for ensuring 
antimicrobial use at your facility? 
If YES, has this pharmacist had 
specialized training in infectious disease 
management or stewardship? 
  Does the lead AM pharmacist have > 3 
years experience in this specialist role? 
Does the lead AM pharmacist have a 
higher qualification than first degree 
(e.g. Diploma/MSc)? 
Does the lead AM pharmacist have 
specialist training in infection 
management /antimicrobial use 
Does your facility have facility-specific treatment 
recommendations based on local antimicrobial 
susceptibility to assist with antimicrobial selection 
for common clinical conditions:  
If YES, for surgical prophylaxis? 






If YES, for community-acquired 
pneumonia? 
   
If YES, for urinary tract infection    
If YES to any of the clinical conditions 
above, are these treatment 
recommendations easily accessible to 
prescribers on all wards (printed ‘pocket 
guide’ or electronic summaries at 
workstations) 
   
Are any of the following actions implemented in 
your facility to improve antibiotic prescribing? 
Standardized criteria for changing from 
intravenous to oral antimicrobial therapy 
in appropriate situations? 
Guidelines/guides for iv–oral 
switch available 
[As above] updated biannually 
 
 Are there IV to Oral switch guidelines? 
Dose optimization 
(pharmacokinetics/pharmacodynamics) to 
optimize the treatment of organisms with 
reduced susceptibility? 
  Is there guidance on dosing 
optimisation for AMs with a narrow 
therapeutic index? 
Discontinuation of specified antimicrobial 
prescriptions after a pre-defined 
duration? 
Time-limited drug 
delivery/automatic stop order 
available 
  
Does your facility measure the percentage of 
antimicrobial prescriptions that are consistent 
with the local treatment recommendations for 
either UTI or CAP? 
 
Did your hospital carried out 
prescribing practice audit last year?  
 
If yes, were results discussed during an 
antibiotic committee?  
 
If yes, were results discussed during an 
infection control committee? 
 
If yes, did you perform feedback to 
prescribers? 
Is adherence to pertinent treatment 
guidelines audited in each specialty and 
fed back at least once a year? 
 
Does your facility audit or review surgical 








If YES, are antimicrobial prescriptions 
compliant with facility-specific guidelines 









Table 10. TATFAR indicators compared to CDC Core Elements of Hospital ASPs checklist 
TATFAR Core Indicators 
 (17 Questions) 
CDC Checklist 
(39 questions) 
Does your facility have a formal antimicrobial stewardship program 
accountable for ensuring appropriate antimicrobial use?  
 
Does your facility have a formal organizational structure responsible for 
antimicrobial stewardship (e.g., a multidisciplinary committee focused on 
appropriate antimicrobial use, pharmacy committee, patient safety committee 
or other relevant structure)?  
Does your facility have a formal, written statement of support from leadership that 
supports efforts to improve antibiotic use (antibiotic stewardship)? 
Is an antimicrobial stewardship team available at your facility (e.g., greater 
than one staff member supporting clinical decisions to ensure appropriate 
antimicrobial use)?  
Does any of the staff below work with the stewardship leaders to improve antibiotic 
use? 
Clinicians  
Infection Prevention and Healthcare Epidemiology  
Quality Improvement   
Microbiology (Laboratory) 
Information Technology (IT)  
Nursing 
Is there a physician identified as a leader for antimicrobial stewardship 
activities at your facility?  
Is there a physician leader responsible for program outcomes of stewardship 
activities at your facility? 
Is there a pharmacist responsible for ensuring antimicrobial use at your 
facility? 
Is there a pharmacist leader responsible for working to improve antibiotic use at 
your facility? 
Does your facility provide any salary support for dedicated time for 
antimicrobial stewardship activities (e.g., percentage of full-time equivalent 
(FTE) for ensuring appropriate antimicrobial use)? 
Does your facility receive any budgeted financial support for antibiotic stewardship 
activities (e.g., support for salary, training, or IT support)? 
Does your facility have the IT capability to support the needs of the 
antimicrobial stewardship activities? 
Above questions incorporates IT 
  
Does your facility have facility-specific treatment recommendations based on 
local antimicrobial susceptibility to assist with antimicrobial selection for 
common clinical conditions? 
Does your facility have facility-specific treatment recommendations, based on 
national guidelines and local susceptibility, to assist with antibiotic selection for 






Does your facility have a written policy that requires prescribers to document 
in the medical record or during order entry a dose, duration, and indication for 
all antimicrobial prescriptions? 
Does your facility have a policy that requires prescribers to document in the medical 
record or during order entry a dose, duration, and indication for all antibiotic 
prescriptions? 
Is it routine practice for specified antimicrobial agents to be approved by a 
physician or pharmacist in your facility (e.g., pre-authorization)? 
Do specified antibiotic agents need to be approved by a physician or pharmacist 
prior to dispensing (i.e., pre-authorization) at your facility?  
Is there a formal procedure for a physician, pharmacist, or other staff member 
to review the appropriateness of an antimicrobial after 48 hours from the 
initial order (post-prescription review)? 
Is there a formal procedure for all clinicians to review the appropriateness of all 
antibiotics 48 hours after the initial orders (e.g. antibiotic time out)? 
Has your facility produced a cumulative antimicrobial susceptibility report in 
the past year? 
Does your facility produce an antibiogram (cumulative antibiotic susceptibility 
report)? 
 
Has a current antibiogram been distributed to prescribers at your facility? 
Does your facility monitor if the indication is captured in the medical record 
for all antimicrobial prescriptions? 
Does your stewardship program monitor adherence to a documentation policy (dose, 
duration, and indication)? 
Does your facility audit or review surgical antimicrobial prophylaxis choice 
and duration? 
 
Are results of antimicrobial audits or reviews communicated directly with 
prescribers?  
Does a physician or pharmacist review courses of therapy for specified antibiotic 
agents (i.e., prospective audit with feedback) at your facility? 
(No communication wording) 
 
Does you stewardship program share facility-specific reports on antibiotic use with 
prescribers? 
 
Do prescribers ever receive direct, personalized communication about how they can 
improve their antibiotic prescribing? 
Does your stewardship program provide education to clinicians and other relevant 
staff on improving antibiotic prescribing? 
Does your facility monitor antimicrobial use by grams [Defined Daily Dose 
(DDD)] or counts [Days of Therapy (DOT)] of antimicrobial(s) by patients per 
days? 
Does your facility monitor antibiotic use (consumption) at the unit and/or facility 
wide level by one of the following metrics: 
 
By counts of antibiotic(s) administered to patients per day (Days of Therapy; 
DOT)? 






By direct expenditure for antibiotics (purchasing costs)? 
Has an annual report focused on antimicrobial stewardship (summary 
antimicrobial use and/or practices improvement initiatives) been produced for 
your facility in the past year? 
Does you stewardship program share facility-specific reports on antibiotic use with 
prescribers? 
 
TATFAR Supplemental Indicators 
(16 questions) CDC Checklist 
Does your facility have a named senior executive officer with accountability for 
antimicrobial leadership? 
 
Is an antimicrobial stewardship team available at your facility (e.g., greater than one 
staff member supporting clinical decisions to ensure appropriate antimicrobial use)? 
If YES, Is an infection preventionist or hospital epidemiologist involved in 
stewardship activities? 
Does any of the staff below work with the stewardship leaders to improve 
antibiotic use? 
Clinicians  
Infection Prevention and Healthcare Epidemiology  
Quality Improvement   
Microbiology (Laboratory) 
Information Technology (IT)  
Nursing  
If YES, Is a microbiologist (laboratory staff) involved in stewardship 
activities? 
See above 
Is clinical infectious disease (ID) consultation available at your facility?  
Is there a physician identified as a leader for antimicrobial stewardship activities at 
your facility?  
If YES, Are stewardship duties included in the job description and/or annual 
review? 
 
If YES, Is this physician trained in infectious diseases, clinical microbiology 
and/or antimicrobial stewardship? 
 
Is there a pharmacist responsible for ensuring antimicrobial use at your facility? 
If YES, has this pharmacist had specialized training in infectious disease 
management or stewardship? 
 
Does your facility have facility-specific treatment recommendations based on local 
antimicrobial susceptibility to assist with antimicrobial selection for common clinical 
conditions:  
Does your facility have specific interventions in place to ensure optimal use of 






If YES, for surgical prophylaxis? Community-acquired pneumonia  
Urinary tract infection 
Skin and soft tissue infections 
Surgical prophylaxis 
Empiric treatment of Methicillin-resistant Staphylococcus aureus (MRSA) 
Non-C. difficile infection (CDI) antibiotics in new cases of CDI 
Culture-proven invasive (e.g., blood stream) infections 
Does your stewardship program monitor compliance with one of more of the 
specific interventions in place? 
If YES, for community-acquired pneumonia? 
If YES, for urinary tract infection 
If YES to any of the clinical conditions above, are these treatment 
recommendations easily accessible to prescribers on all wards (printed 
‘pocket guide’ or electronic summaries at workstations) 
Are any of the following actions implemented in your facility to improve antibiotic 
prescribing? 
Standardized criteria for changing from intravenous to oral antimicrobial 
therapy in appropriate situations? 
Automatic changes from intravenous to oral antibiotic therapy in appropriate 
situations? 
Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the 
treatment of organisms with reduced susceptibility? 
Automatic changes from intravenous to oral antibiotic therapy in appropriate 
situations? 
Dose adjustments in cases of organ dysfunction? 
Discontinuation of specified antimicrobial prescriptions after a pre-defined 
duration? 
Time-sensitive automatic stop orders for specified antibiotic prescriptions? 
Does your facility measure the percentage of antimicrobial prescriptions that are 
consistent with the local treatment recommendations for either UTI or CAP? 
Does your stewardship program monitor adherence to facility-specific 
treatment recommendations? 
Does your facility audit or review surgical antimicrobial prophylaxis choice and 
duration? 
If YES, are antimicrobial prescriptions compliant with facility-specific 
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